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Mass spectrometry-based proteomics is a powerful tool when combined 
with hypothesis driven protein purification.  Regulation of protein-protein 
interactions is a major molecular mechanism for gene activation.  Protein 
purification, functional assays, and antibody-based western blots have 
traditionally been used to elucidate many of the most critical and perhaps 
universal protein-protein interactions required for gene expression, such as the 
assembly of the general transcription machinery.  The Mediator complex is an 
essential part of the general transcription machinery that integrates signals from 
DNA-binding transcriptional activators through protein-protein interactions to 
regulate RNA Pol II activity.  Gene activation is ultimately determined by 
incoming stimuli and subsequent inter-cellular signaling.  How these signals are 
integrated in a spatial and temporal fashion for the regulation of distinct genes by 
activator-Mediator interactions is unclear. 
One proposed molecular mechanism of gene activation by the Mediator 
complex is through a structural shift in the complex.  Mediator structural shifts 
may trigger new protein-protein interactions required for transcription of select 
genes in response to a specific stimulus. To test this, Mediator complexes were 
purified with and without transcriptional activators.  The activation domains of the 
iii 
transcriptional activators SREBP-1a and VP16, which generate distinct structures 
upon binding Mediator, were used to affinity purify activator-bound Mediator 
complexes.  For comparison, antibodies for the Mediator subunits MED1 and 
CDK8 were used to affinity purify activator-free Mediator complexes.  A mass 
spectrometry-based proteomics platform was established to characterize the 
protein compositions of each Mediator complex purification.  The results showed 
additional cofactors in the activator-bound Mediator complexes, many of which 
had known function related to gene expression.  Selected cofactors were 
validated for binding Mediator with an orthogonal purification that combined the 
activator and antibody purifications and western blotting.  Together the 
proteomics data predicted and the western blotting confirmed new protein-protein 
interactions relevant for regulation of gene expression that were activator-specific. 
If activator-binding triggers new Mediator-cofactor interactions, could 
distinct activators induce distinct protein complexes that were gene-specific?  
This was shown upon comparing SREBP-1a and VP16.  To further test this idea, 
other activators were used to purify Mediator complexes, and the associated 
polypeptides were again identified using MS-based proteomics.  We evaluated 
Mediator complexes bound to one of three isoforms of SREBP: SREBP-1a, 
SREBP-1c or SREBP2.  These three isoforms of SREBP were compared and 
unique cofactors identified.  Another comparison of the activators p53 and p65 
was also performed, with unique cofactors identified with each.  These data 
provide further evidence that gene-specific protein complexes can be 
coordinately assembled upon activator-Mediator binding.  Collectively, these 
iv 
targeted proteomics approaches have generated many new hypotheses and 
have fundamentally altered our understanding of how gene expression is 
regulated. 
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Chapter 1 
 
Introduction –– Background and Significance 
________________________________________________________________ 
 
 
 
 The first draft of the human genome was completed ten years ago (Venter, 
et al., 2001), providing a comprehensive view of the nearly three billion base 
pairs (bp) of DNA found in every cell of a human being.  However, knowing the 
sequence of DNA that make up each gene does not unfortunately provide many 
clues as to how the expression of a gene is regulated, nor how the genome 
directly controls the function of any given cell.  Elusive are the complexities of the 
development from a single cell zygote to a fully functional adult human. 
 The central dogma of molecular biology proposed by Watson and Crick 
dictates the flow of information proceeds very simply from DNA to RNA to protein.  
DNA must be replicated for cell division, however, once a cell state is defined 
and the cell goes to work, the expression of many genes (Class II) ultimately 
proceeds to protein.  The processing of DNA into RNA is known as transcription.  
RNA, specifically messenger RNA (mRNA), is converted into protein through a 
process known as translation.  There are many molecular mechanisms for 
regulating gene expression of protein coding genes. 
 
 
 
1 
1.1 Cellular Organization and Genome Function 
 
 All of the DNA that makes up each of our 46 chromosomes must be 
packaged into each cell.  Approximately 146bp of DNA is wrapped around an 
octamer of histone proteins known as a nucleosome (Figure 1.1.B).  The ordered 
assembly of nucleosomes is referred to as chromatin.  Chromatin is organized 
into higher order structures that can be visualized as dense chromosomes 
(Figure 1.1.A, bottom).  Chromatin presents one barrier for transcription factors 
that must be negotiated by chromatin remodeling factors (Narlikar, et al., 2002). 
 
         A         B 
   
 
Figure 1.1  Architecture of a Chromosome.  (A) DNA is packaged by wrapping 146bp 
around an octamer of histones to form ‘Beads on a string’, then further condensed into 
chromati (Felsenfeld & Groudine, 2003).  (B) Crystal structure of a nucleosome (Luger, 
2003). 
 
 
 Cells are organized into distinct organelles and compartment with a 
functional organization.  The nucleus is much the same with distinct areas of 
inactive genes and compartments with high gene expression activity.  In these 
2 
nuclear domains of high activity are many of the factors required for effective 
gene expression:  transcription factors, chromatin remodeling proteins and 
mRNA-processing factors (Misteli, 2007).  Chromosomes can be visualized using 
fluorescent probed and assigned positions in three-dimensions (Figure 1.2).  
Some chromosomes are localized in the nucleus relative to the center, while 
others localize to the edges, with preferred groups of adjacent chromosomes 
(Meaburn and Misteli, 2007). 
 
    
Figure 1.2  Visualization of all chromosomes simultaneously in a human fibroblast 
(Meaburn and Misteli, 2007). 
 
 
 Why and how some chromosomes localize to the center of the nucleus 
while other to the periphery is unknown.  What is significant is that patterns of 
chromosome positioning is similar among cell types with common developmental 
3 
pathways and that chromosome positions in a given cell type are conserved 
(Meaburn and Misteli, 2007). 
 There are two theories of how chromosomes are positioned in the nucleus.  
One possibility is that a chromosome is positioned by anchoring to a nuclear 
scaffold.  This would require some mechanism for tethering chromosomes with 
encoded positioning information.  It could be envisioned that molecular motors 
would be involved for translocation of chromosome through the nuclear scaffold.  
A second possibility is that chromosome position is determined by the pattern of 
active and silent genes on any given chromosome.  The local chromatin structure 
would be affected by the level of gene activation.  Highly active genes have 
decondensed chromatin (euchromatin) where inactive genes are more 
condensed (heterochromatin).  Therefore, the self-organization of a chromosome 
could be affected by the amount of euchromatin and heterochromatin (Misteli, 
2007; Lanctôt, et al., 2007) 
 Compartmentalization of the nucleus allows for the concentration of 
factors necessary for dedicated functions, such as transcription, replication and 
DNA repair (Figure 1.3).  An advantage of such a system would be that a single 
cofactor could be multifunctional depending on the compartment and the other 
cofactors present.  For example, a population of activated transcription factors 
could divide the duties, with some targeting transcription and chromatin 
remodeling proteins while others target the designated chromosome, recruit 
motor proteins to escort the chromosome to a compartment enriched in 
4 
transcription factors ready to activate gene expression.  This is an interesting 
hypothesis. 
 
    
Figure 1.3  Organization of the Mammalian Cell Nucleus (Lanctôt, et al., 2007).  The 
nucleus is compartmentalized for distinct functions.  Nuclear pores are found in the nuclear 
envelope to regulate what goes into and out of the nucleus.  The nuclear lamina is a mesh 
of filaments to maintain shape and structure.  Chromatin is organized into chromatin 
territories.   
 
 
1.2 Transcription Factories 
 
 Visualization of transcription shows thousands of distinct sites distributed 
throughout the nucleus (Figure 1.4.A) (Wansink, et al., 1993; Misteli, 2007). One 
view is that these are subnuclear transcription centers, or “transcription factories” 
5 
(Cook, 1999; Chakalova, et al., 2005), with a density of polymerase and all other 
relevant transcription factors present and in sufficient abundance for multiple 
genes (Cook, 1999).  If there is an estimated 65,000 RNA Pol II molecules and 
10,000 transcription sites in HeLa cell, then there would be approximate six Pol II 
per site (Misteli, 2007).  This concept is analogous to RNA Pol I transcription in 
specialized centers (Raska, et al., 2006). 
 With thousands of compartmental transcription factories (Figure 1.4.A), it 
seems plausible that the composition of transcription factors could be distinct in 
different compartments.  How cofactors would be delivered to the correct 
compartment could be complex.  What is known is that transcription and  
 
   
Figure 1.4  Compartmentalization of Nuclear Processes (Misteli, 2007).  Transcription sites 
(A), replication sites (B) and DNA repair sites (C) visualized in the nucleus. 
 
6 
chromatin proteins bind and release in a few seconds (Phair, et al., 2004) 
allowing the sampling of the nuclear space for high affinity binding sites.  
Therefore, the stable protein-protein interactions in these sites would likely be 
highly regulated and protein complexes could be quite large.  These complexes 
would likely include chromatin remodeling factors, the Mediator complex and 
other coactivators such as SAGA and p300/CBP as well as the general 
transcription machinery and RNA Pol II. 
 
1.3 Gene Expression Requires General Transcription Factors 
 
 Eukaryotic organisms all employ a universal subset of general 
transcription factors (GTFs) for gene expression of protein-coding genes, which 
include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH and the Mediator complex 
(Thomas and Chang, 2006).  The complex of GTFs and Mediator has historically 
been known as the pre-initiation complex (PIC).  The PIC including RNA Pol II at 
~4MDa is elongation ready, therefore, it is really more of a pre-elongation 
complex (PEC) (Figure 1.5) (Taatjes, 2010).  The role of the PEC is to recognize 
the promoter of protein-coding genes and bring RNA Pol II to the start site of the 
gene. 
 
7 
 Figure 1.5  The General Transcription Machinery. (Taatjes, 2010)  Each component is 
shown at a scale representative of each factor.  *TFIIA is processed into three subunits.  
**TFIID composition varies. 
 
 
There are two popular models for activated transcription.  The first model is that a 
transcription activator targets chromatin remodeling factors to allow access to the 
gene promoter.  The general transcription machinery can then assemble and 
initiate transcription.  The second model is that the transcription activator binds to 
the DNA to nucleate the Mediator complex, RNA Pol II and the GTFs, forming the 
PEC to initiate transcription.  Both models involve the recruitment of cofactors for 
activation; either chromatin remodeling factors (Narlikar, et al., 2002) (first model), 
or transcription proteins (second model).  In fact, it is quite reasonable that both 
models can coexist at some genes at least.  A transcription activator can bind 
chromatin remodeling factors to remove nucleosomes allow access to the 
enhancer binding site, where the GTFs can then be nucleated.  These protein-
protein interactions would need to be highly coordinated and tightly regulated for 
the appropriate amount of gene expression.  The Mediator complex is an ideal 
candidate for a central regulator. 
8 
1.4 The Transcription Cycle of RNA Pol II 
 
 The traditional view of gene activation, or transcription, is (1) initiation 
(assembly of PEC), (2) elongation (promoter escape), and (3) termination 
(transcript cleavage and polyadenylation).  The nascent mRNA is then spliced to 
remove introns, packaged and exported out of the nucleus for translation in the 
cytoplasm.  The prevailing view is that transcription elongation and the 
processing of mRNA, 5’ capping, splicing and cleavage/polyadenylation, are 
paired together and occur simultaneously (Figure 1.6) (Orphanides and Reinburg, 
2002; Perales and Bentley, 2009).  The export of mRNA and splicing may also 
be coupled (Reed and Hurt, 2002).  Central to coordinating transcription and 
RNA processing is the C-terminal domain (CTD) of the largest subunit of RNA 
Pol II.  The CTD consists of repeats of the heptad sequence YSPTSPS, which 
varies in number from organism to organism depending on genomic complexity.  
The yeast Saccharomyces cerevisiae has 26~27 repeats, Drosophila as 45 
repeats, and humans and mice have 52 repeats (Bartkowiak and Greenleaf, 
2011).  The CTD is not required for catalytic activity of the polymerase, but a 
minimum length is required for viability (Phatnani and Greenleaf, 2006).  RNA 
processing and the CTD were coupled from an experiment where newly 
synthesized RNA was crosslinked to a hyperphosphorylated form of the CTD.  It 
is now known that the CTD is a large scaffold for binding cofactors throughout 
the transcription cycle (Phatnani and Greenleaf, 2006).  Dynamic reversible post-
translational modifications affects the binding specificity of the CTD.  The 
9 
  
  
 
Figure 1.6  The RNA Pol II transcription cycle connects each step in a continuous process 
(Orphanides and Reinberg, 2002).  Initiation and 5’ mRNA capping are coupled.  Transcription 
elongation and mRNA processing are coupled.  mRNA processing and export may also be 
coupled. 
 
 
phosphorylated form of the CTD helps to recruit capping factors to the 5’ end of 
new mRNAs and 3’ processing factors to poly(A) sites.  The potential for 
differential modifications suggests a “CTD code” (Buratowski, 2003).  
Phosphorylation of tyrosine, threonine and all three serines of the CTD repeats 
have been detected in vivo (Egloff and Murphy, 2008).   
 
10 
  
 
Figure 1.7  The RNA Pol II CTD Coordinates Transcription and Pre-mRNA Processing 
(Orphanides and Reinberg, 2002).  The CTD is 52 repeats of YSPTSPS which functions as a 
platform for the ordered assembly of pre-mRNA 5’ capping, splicing and termination.   
 
 The CTD binds the Mediator complex in the PEC in the unphosphorylated 
form called Pol II (A) (Kim, et al., 1994; Näär, et al., 2002) (Figure 1.7 number 1).  
The CDK7 kinase subunit of the GTF TFIIH phosphorylates the serine 5 and 
serine 7 of the repeat.  This activity is dependent on the Mediator complex 
11 
(Meyer, et al. 2010; Boeing, et al., 2010; Glover-Cutter, et al., 2009) and it is 
thought that this event disrupts the PEC and induces dissociation of the Mediator 
complex (Figure 1.7 number 2) (Max, et al., 2007; Svejstrup, et al., 1997). This 
early phosphorylation mark induces the recruitment of 5’ capping enzymes.  
Further phosphorylation of the CTD by the positive transcription elongation factor 
b (P-TEFb) phosphorylates serine 2 is consistent with promoter escape and the 
recruitment of pre-mRNA splicing machinery (Figure 1.7 number 3) (Orphanides 
and Reignberg, 2003; Bartkowiak and Greenlead, 2011; Egloff and Murphy, 
2008).  Serine 2 phosphorylation persists through the 3’ end of the gene and may 
recruit cleavage and 3’ polyadenylation factors (Figure 1.7 number 4).  Some of 
the phosphorylation-specific cofactors that bind the CTD throughout the 
transcription cycle are shown in Figure1.8.  The number of sites phosphorylated 
or any specific pattern is completely unknown.  Due to the number of sites in the 
heptad that can be phosphorylated and the number of repeats, there are a 
significant number of possible combinations of CTD phosphorylation (Figure 1.9).  
There are two prolines in each repeat that can be in either cis or trans orientation 
giving four possible combination for each repeat (Figure 1.9) (Egloff and Murphy, 
2008).  Peptidyl-prolyl cis/trans isomerases (PPIases), such as Pin1, may 
catalyze isomerization of CTD prolines in vivo.  They target phosphorylated CTD 
with a high affinity for pSP and pTP (Xu and Manley, 2004, 2007).  Phosphatases 
then remove the phosphorylation marks to reset the Pol II molecule for 
subsequent rounds of transcription. 
 
12 
 Figure 1.8  The CTD Code and selective binding of protein (Egloff and Murphy, 2008).  (a) 
Factors involved in histone modification, 5’ mRNA capping, splicing, and 3’ mRNA processing 
bind the phosphorylated CTD.  (b) The integrator complex binds the CTD for small nuclear RNA 
processing (Egloff, et al., 2007). 
 
 
Figure 1.9  The Complexity of the CTD Code (Egloff and Murphy, 2008).   
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 A second large protein complex that directly binds the CTD is the 
Integrator complex.  The Integrator complex is evolutionarily conserved and 
made up of 12 subunits for ~2MDa.  The function of this complex is processing 
Pol II mediated-small nuclear RNAs (snRNAs) (Baillat, et al., 2005).  Furthermore, 
serine 7 phosphorylation of the CTD repeat is required for snRNA processing 
(Egloff, et al., 2007). 
 
1.5 The Mediator Complex is Regulated by Structural Shifts 
 
 The Mediator complex is a co-activator that regulates gene activation by 
regulating RNA Pol II.  As mentioned earlier, Mediator is really a general 
transcription factor that is absolutely required for expression of protein-coding 
genes.  Mediator is 26 subunits and1.2 MDa with an enormous surface area for 
protein-protein interactions.  It is at the heart of the PEC and serves as a 
molecular bridge connecting DNA-bound activators and the GTFs.  Various 
subunits are targeted by a number of activators (Figure 1.10) (Taatjes, et al., 
2004; Malik and Roeder, 2010).  The large size of Mediator accommodates a 
structural plasticity and enormous potential for protein-protein interactions 
(Taatjes, 2010).   
The activator sterol regulator element-binding protein (SREBP) binds the MED15 
subunit of the Mediator complex.  As a result, MED15 may serve as a master  
14 
regulator of lipid homeostasis (Malik and Roeder, 2010).  The tumor suppressor 
p53 has been shown to target MED17 and MED1 subunits, while the viral 
activator VP16 targets MED25.  Nuclear receptors target MED1.  The activators 
 
 
 
 
Figure 1.10  Modular structure of Mediator and interactions with diverse activators (Malik and 
Roeder, 2010).  Transcription activators are shown with their respective Mediator target subunits. 
15 
  
Figure 1.11  Activator-induced conformational shift in Mediator structure (Taatjes, et al., 2004).  
(a) SREBP-1a and (b) VP16 bind the MED15 and MED25 subunits, respectively.  The yellow 
shows the approximate binding site for VP16 and the green for SREBP-1a. (c) An alternative view 
of unliganded Mediator rotated 90º. 
 
 
SREBP and VP16 were used in a study to show that activator-binding induces a 
global structural shift in the complex that is distinct for each activator (Figure 
1.11) (Taatjes, et al., 2002, 2004). 
An activator-dependent structure shift would be an elegant molecular 
mechanism for regulating protein-protein interactions.  Unique Mediator 
16 
structures are also found with the nuclear receptors vitamin D receptor (VDR) 
and the thyroid receptor (TR) (Figure 1.12).  Despite the fact that many activators 
bind the Mediator complex, the unique conformation induced by an activator may 
confer promoter-specific function dependent on Mediator structure (Figure 1.12).  
The recruitment of enzymatic activities such as chromatin remodeling factors or 
gene-specific mRNA processing factors could be very tightly regulated with this 
type of mechanism. 
unliganded Mediator
VP
16
SR
EB
P
VD
R
TR
p53N
-term
inus
CTD
 
 
Figure 1.12  Activator-specific structural states of the Mediator complex.  A RNA Pol II CTD-
bound structure is also included for comparison. 
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 1.6 Mass Spectrometry-based Proteomics Unifies Mediator 
 
 Mediator purified in different laboratories were given a different name, 
creating a variety of names for virtually the same Mediator complex.  It was 
called TRAP/SMCC (thyroid hormone receptor-associated proteins/SRB-Med-
containing cofactor), ARC-L (activator-recruited factor-large), DRIP (vitamin D 
receptor-interacting proteins), mouse Mediator, rat Mediator, PC2 (positive 
cofactor 2) and CRSP (cofactor required for Sp1 activation) (Sato, et al., 2004).  
To define the subunit composition of the Mediator complex Sato, et al. employed 
multidimensional protein identification technology (MudPIT) (Washburn, et al., 
2001), which is a mass spectrometry-based method capable of thoroughly 
characterizing a complex protein sample.  Five different subunits of the Mediator 
complex were stably transfected in HeLa cells with a Flag-tag.  Thirty Mediator 
subunits were identified (Figure 1.13) as a set of consensus mammalian subunits.  
At about the same time, a unified nomenclature was agreed upon for all Mediator 
subunits (Bourbon, et al. 2004).  The methodology used by Sato, et al., 2004, is 
very powerful for characterizing protein complexes.  This type of mass 
spectrometry analysis is now more widely used for the study of protein-protein 
interactions such as molecular machines and protein networks (Kocher and 
Superti-Furga, 2007), signaling networks (Choudhary and Mann, 2010) as well 
as affinity purifications (AP-MS) (Gingras, et al., 2007). 
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 Figure 1.13  Consensus Mediator Subunits Identified by MudPIT (Sato, et a., 2004).  Mammalian 
Mediator subunits identified in different Flag-tagged Mediator subunits.  Mediator purified in 
different labs received different names. (A) Red boxes indicate Mediator subunits present in 
TRAP/SMCC, ARC, DRIP, CRSP, PC2, mouse and rat Mediator.  (B) Sequence coverage for 
identified subunits (red) for each Flag-tagged Mediator fraction.  (C) Phosphocellulose fractions 
show two distinct Mediator complexes. 
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1.7 Thesis Overview 
 
 The proper regulation of protein-protein interactions in a spatial and 
temporal fashion is absolutely fundamental for gene expression.  The nucleus of 
a cell is crowded with proteins binding and unbinding.  The Mediator complex is a 
large protein complex with enormous surface area for protein-protein interactions.  
Distinct activators induce unique structures for the complex, which could be an 
elegant molecular mechanism for regulating protein-protein interaction.  Only 
when a transcription activator is bound to the enhancer would it be required to 
recruit transcription cofactors. 
 In Chapter 2, we provide evidence for the hypothesis that an activator-
induced structural shift in the Mediator complex induces new protein-protein 
interactions.  We apply the MudPIT protocol, used to identify the consensus 
Mediator subunits, to characterize purified Mediator complex without activator 
ligand and activator-bound Mediator both from HeLa nuclear extract.  We identify 
a subset of cofactors only found in the activator-bound Mediator fractions.  Select 
cofactors were characterized with biochemical assays to assess if they were 
Mediator-bound or activator-bound.  A few were bound only to the activator, while 
most were Mediator-associated. 
 Chapter 3 details a method development strategy to improve the mass 
spectrometry methodology.  Many activator-Mediator fractions would be too 
dilute for the MudPIT analysis used in Chapter 2.  Futhermore, technical issues 
drove the development of an all new method.  Significant changes were made to 
20 
the protein precipitation and proteolysis strategies as well as the 
multidimensional chromatography used.  Implemented modifications vastly 
improved sensitivity and ruggedness.  A Mediator immunoprecipitation and a 
activator-Mediator fraction are analyzed with the improved method and directly 
compared to data generated using the MudPIT strategy.  Samples of less than 1 
ug highly purified Mediator and 2 ug RNA Pol II are also analyzed to demonstrate 
the sensitivity of the assay.  All subunits of each complex were identified. 
 In Chapter 4, we put the new improved proteomics platform to work 
characterizing activator-Mediator fractions from all three isoforms of sterol 
regulatory element-binding protein (SREBP), p53 and p65/RelA.  Unique 
cofactors as well as Mediator and RNA Pol II are identified with each activator.  
Many interesting hypotheses can be derived from the datasets. 
 Chapter 5 focuses more on the RNA Pol II CTD.  To probe the 
interactome of the full length endogenous CTD, a GST-fusion was used to purify 
CTD-interacting cofactor which were then identified using the proteomics 
platform.  Next, CTD kinases were purified and used to phosphorylate the CTD in 
vitro to again purify phospho-CTD-interacting cofactors.  The kinases TFIIH and 
P-TEFb were used individually and combined to generate distinct 
phosphorylation patterns on the CTD.  Unique cofactors are again identified with 
each phospho-form of the CTD.  Finally, preliminary data is shown for a mass 
spectrometry-based strategy to identify exact residues of phosphorylation 
throughout the length of the CTD.  This method would enable the determination 
of a CTD code, or a unique pattern of modification on the CTD. 
21 
________________________________________________________________ 
 
Chapter 2 
 
Activator-Mediator Binding Regulates Mediator-Cofactor Interactions 
________________________________________________________________ 
 
 
 The 26-subunit, 1.2 MDa human Mediator complex is essential for 
expression of perhaps all protein-coding genes.  Activator binding triggers major 
structural shifts within Mediator, suggesting a straightforward means to spatially 
and temporally regulate Mediator activity.  By using MudPIT mass spectrometry 
and other techniques, we have compared the subunit composition of Mediator in 
three different structural states:  (1) bound to the activator SREBP-1a, (2) bound 
to the activator VP16, or (3) an activator-free state.  As expected, consensus 
Mediator subunits were similarly represented in each sample.  However, we 
identify a set of cofactors that interact specifically with activator-bound but not 
activator-free Mediator, suggesting activator binding triggers new Mediator-
cofactor interactions.  Furthermore, MudPIT combined with biochemical assays 
reveals a non-overlapping set of co-regulatory factors associated with SREBP-
Mediator vs. VP16-Mediator.  These data define an expanded role for activators 
in regulating gene expression in humans and suggest that distinct, activator-
induced structural shifts regulate Mediator function in gene-specific ways. 
 
 
 
 
22 
2.1 Introduction 
 
 Transcriptional regulation is driven in large part by transcription factors: 
DNA-binding proteins that target specific regulatory sites within the genome. 
Different transcription factors (or activators) recognize different sequence 
elements via their DNA-binding domains, whereas distinct activation domains 
within transcription factors interact with one or perhaps several components of 
the transcriptional machinery.  One of the main activator targets within the 
transcriptional machinery is the Mediator complex (Conaway, et al., 2005; Malik 
& Roeder, 2005).  Direct activator-Mediator interactions are thought to recruit and 
stabilize Mediator at the promoter; however, EM analyses of Mediator bound to 
different activation domains have indicated that activators may be playing other 
regulatory roles (Taatjes, et al., 2004).  In particular, activator binding induces 
significant structural shifts within Mediator (Taatjes, et al., 2002), which imply an 
additional means to regulate the human Mediator complex.  The sheer size 
(approximately 320 × 180 × 160 Å) and shape of Mediator provides an enormous 
surface area for protein–protein interactions, and the global structural shifts 
induced by activator binding likely expose distinct motifs within the Mediator 
complex.  Potentially, such structural shifts may activate Mediator by triggering 
protein–protein interactions at the promoter. 
 To test this hypothesis, we purified Mediator in three different structural 
states.  In one instance, Mediator was purified bound to the activator SREBP-1a; 
in another, Mediator was purified bound to the activator VP16; Mediator was also 
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purified in an activator-free state (without an activator bound).  Relative to the 
activator-free conformation, Mediator will adopt significantly different structural 
states when bound to SREBP-1a vs. VP16 (Taatjes, et al., 2002)).  To assess 
Mediator subunit composition and potential associated factors in each structural 
state, we utilized the multidimensional protein identification technology (MudPIT) 
methodology, which enables a comprehensive, unbiased assessment of protein 
composition within even highly complex samples (Chen, et al., 2006). Our results 
provide clear evidence that activator-induced structural shifts trigger Mediator-
cofactor interactions.  Moreover, a subset of factors interact specifically with 
SREBP-Mediator but not VP16-Mediator, suggesting distinct activator-dependent 
structural shifts within Mediator direct gene-specific regulatory functions.  These 
data indicate that activator binding can dictate subsequent Mediator-cofactor 
interactions, providing a straightforward means by which Mediator activity (i.e., 
transcription) can be controlled in a spatial and temporal fashion. 
 
2.2 Results 
 
 The MudPIT method uses a two-dimensional liquid chromatography 
separation method coupled to a tandem mass spectrometer for detection of 
tryptic peptides.  A major advantage of this technique is that protein samples are 
digested in solution, which minimizes sample loss that is typical for standard in-
gel protein sample preparation methods.  This feature is especially important for 
24 
analysis of Mediator, given the low-abundance of this macromolecular complex in 
human cells. 
 
2.2.1 Activator-Induced Structural Shifts Do Not Dissociate any 
Mediator Subunits. 
 
 In past studies, we have purified 
human Mediator by using a combination of 
ion exchange and affinity chromatography 
steps, followed by glycerol gradient 
sedimentation.  This rigorous purification 
protocol yields Mediator complexes that are 
devoid of additional associated factors.  
The purpose of this work was to use 
MudPIT to address whether additional 
cofactors might stably interact with M
and, if so, whether these interaction
dependent upon activator-induced M
structural shifts.  Consequently, we adopted 
a simplified purification scheme such tha
potential Mediator-associated factors co
be identified (Figure 2.1).  Importantly,
simplified purification protocol still includ
ediator 
s were 
ediator 
t 
uld 
 the 
ed 
Figure 2.1.  Purification protocols for 
MudPIT samples.  (A) Activator-free 
Mediator immunoprecipitation 
purification scheme.  (B) Activator-
bound Mediator purification scheme.
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a series of high-salt washes to remove weak, nonspecific interactions.  To p
Mediator in an activator-free state, we isolated complexes from HeLa nuclear 
extract by using antibodies against the Med1 or CDK8 subunits.  Activator-bo
Mediator complexes were purified with affinity chromatography resins containing 
the activation domain of VP16 (residues 411–490) or SREBP-1a (residues 1–50
After elution, the activator-bound Mediator samples were further purified ove
glycerol gradient, and Mediator-containing fractions (>1 MDa in size) were 
combined for MudPIT analysis. 
 Afte
urify 
und 
).  
r a 
r analysis of Mediator samples with the MudPIT protocol, identified 
 were 
le 
ted 
, 
.  
 
ere 
peptides were subjected to a rigorous 1% false discovery rate threshold; 
furthermore, peptides that could be assigned to multiple different proteins
assigned with the Isoform Resolver algorithm (Meyer-Arendt, et al., 2011) and 
quantified by the spectral counting method (Old, et al., 2005).  As shown in Tab
2.1, all consensus Mediator subunits (Sato , et al., 2004) were identified in each 
sample (SREBP-Mediator, VP16-Mediator, CDK8 IP, and Med1 IP), with one 
exception:  Med26 was not observed in the CDK8 IP sample.  This was expec
upon the basis of past work that demonstrated a mutually exclusive association 
of CDK8 and Med26 within Mediator (Taatjes, et al.,2002).  Total spectral counts
defined as an MS/MS event identifying a peptide corresponding to a specific 
protein, are shown for each of the four different Mediator samples in Table 2.1
With a few exceptions, spectral counts were similar—typically within a 2- to 3-fold
range—for each of the 32 consensus Mediator subunits (26 core Mediator 
subunits, plus the CDK8 submodule).  Moreover, when all spectral counts w
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summed for activator-bound Mediator and activator-free Mediator (IPs), there 
was less than a 2-fold difference in total Mediator spectral counts.  Importantly
this indicates the total amount of Mediator was similar within each of the four 
MudPIT samples analyzed.  These data also demonstrate that, whereas activ
binding alters the conformational state of Mediator, activator induced structural 
shifts—at least those induced by SREBP or VP16—do not cause dissociation of
any Mediator subunit. 
 
, 
ator 
 
2.2.2 Activator Binding Triggers Mediator-Cofactor Interactions. 
The data outlined in Table 2.1 represent expected results from MudPIT 
nalys
re 
a 
s 
for 
 
Table 2.2.  Note that for most cofactors, the fold enrichment represents a  
 
 
 
a is of Mediator and are consistent with a previous study by the Conaway 
lab, in which activator-free Mediator samples (i.e., purified with an antibody) we
examined by MudPIT (Sato, et al., 2004).  The motivation for this study, however, 
was to determine whether additional cofactors might preferentially associate with 
activator-bound Mediator complexes, which will adopt distinct structural states 
compared with activator-free Mediator.  As shown in Table 2.2, the MudPIT dat
provide support for the hypothesis that activator-dependent structural shifts 
trigger Mediator-cofactor interactions.  Spectral counts for identified cofactor
were summed for activator-bound Mediator complexes (VP16 or SREBP) and 
activator-free Mediator (CDK8 IP or Med1 IP).  Cofactors identified that were 
greater than 4-fold enriched in activator-bound Mediator samples are shown in
27 
Table 2.1  Spectral Counts for consensus Mediator subunits. 
calculated Mediator
MW (KDa) subunit MED1 CDK8 SREBP VP16
168.4 MED1 30 68 216 159
29.7 MED4 64 37 117 76
28.4 MED6 21 12 10 38
27.2 MED7 1 1 58 16
32.8 MED8 108 19 61 62
16.4 MED9 21 1 9 27
15.7 MED10 25 27 67 35
13.1 MED11 117 92 155 106
160.7 MED14 54 75 140 106
86.8 MED15 106 127 140 165
96.8 MED16 23 18 114 63
72.9 MED17 80 27 148 48
23.7 MED18 12 22 20 43
26.3 MED19 18 9 30 5
23.2 MED20 36 55 29 66
15.6 MED21 60 31 98 64
16.5 MED22 11 51 30 81
156.2 MED23 38 50 121 190
110.3 MED24 181 63 224 137
78.9 MED25 4 7 17 28
65.5 MED26 19 0 40 25
35.4 MED27 3 17 25 16
19.5 MED28 18 3 8 18
23.5 MED29 13 7 20 8
20.3 MED30 2 10 26 5
15.8 MED31 4 4 24 17
53.3 CDK8 2 8 13 2
CDK8 or CDK19 10 4 13 27
56.8 CDK19 3 0 2 6
35.6 Cyclin C 15 5 9 13
243.1 MED12 66 134 270 143
239.2 MED13 44 77 202 84
242.6 MED13L 11 15 74 18
Spectral Counts
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29 
m tectable 
peptides in the activator-free Mediator samples (CDK8 IP or Med1 IP).  To 
ensure that potential Mediator-cofactor interactions were not occurring indirectly 
via any nucleic acid tether, we completed control experiments in which Mediator 
samples were treated with benzonase, a promiscuous endonuclease that cleaves 
both single- and double-stranded RNA or DNA.  Benzonase treatment did not 
affect the presence of Mediator-associated factors, as determined by quantitative 
Western blot analysis.  Furthermore, we performed SREBP-Mediator 
purifications by using a different affinity tag (MBP instead of GST) to confirm that 
the cofactors identified in Table 2.2 did not result from potential interactions with 
GST.  
It was possible that enrichment of some factors listed in Table 2.2, such as 
CBP, might result from a direct interaction with SREBP (Oliner, et al., 1996) and 
not Mediator itself.  Our purification protocol (Figure 2.1) includes a glycerol 
gradient sedimentation step that will separate complexes upon the basis of size; 
complexes of approximately 1.0 MDa and greater were selected for MudPIT 
analysis.  Thus, a 350 kDa SREBP-CBP binary complex (for example) would be 
separated during the glycerol gradient step.  However, as an additional means to 
ensure the factors identified in Table 2.2 associate with SREBP-Mediator and not 
SREBP itself, we completed an orthogonal purification scheme, outlined in Figure 
2.2.A.  This protocol first involved isolation of SREBP-Mediator complexes with 
an SREBP affinity resin, as before.  Following elution from the resin, complexes 
were passed over an anti-Med1 or an anti-CDK8 antibody column to ensure that  
inimum value because most proteins listed in Table 2.2 had no de
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Table 2.2  MudPIT identifies a subset of factors that associate with 
activator-bound Mediator. 
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Table 2.2. Continued.  MudPIT identifies a subset of factors that 
associate with activator-bound Mediator. 
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BA HeLa NE
SREBP-1a
Affinity Column
0.5M KCl Wash       GSH Elution
INPUT
anti-MED1 or anti-CDK8
Immunoprecipitation
0.5M KCl Wash   0.1M Glycine
IP Elution
M
ED
1
C
D
K
8
(-)
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tr
l
250kD
150kD
100kD
75kD
50kD
IN
PU
T
MED13, 12
MED1
TRRAP
MED14
MED23
MED15, 24
MED16, 25
MED17
MED26
CDK8, IgG
IP Elutions
Mr
only Mediator complexes would be retained, whereas potential SREBP-CBP 
complexes (for example) would flow through. After a series of high-salt washes, 
proteins were eluted from the Mediator antibody resin (Figure 2.2.B).  The 
presence or absence of additional Mediator-associated factors was then 
examined by western blot analyses. 
 As shown in Figure 2.3, the results from this orthogonal purification 
protocol confirms that many cofactors identified in Table 2.2 are in fact Mediator-
associated, as they were retained by the second, Mediator-specific antibody 
affinity resin.  Note, however, that the orthogonal purification procedure did 
identify a few cofactors (LRP130, HADHA, SKIV2L2, SnoN) that do not appear to 
interact directly with Mediator and likely associate with SREBP itself.  These 
results highlight the effectiveness of the orthogonal purification strategy in 
Figure 2.2.  Activator binding triggers new Mediator-cofactor interactions.   
(A) Orthogonal purification scheme for confirmation of Mediator-associated cofactors.  
(B) Silver-stained 7% acrylamide gels representing various stages in the orthogonal 
purification:  IP input, A/G-beads only negative control, and CDK8 or MED1 IP elutions.  
Subunit identities are listed at the right. 
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anti-GCN1L1
anti-RUVBL2/
anti-TRRAP
anti-ADA2B
anti-ADA3L
       reptin
anti-MED15
anti-CBP/p300
anti-GCN5L
anti-ATM
IN (-)
 
IP
 
anti-LRP130
anti-SKIV2L2
IN
PU
(-)
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t
IP
 E
l
associated.  
The 12 factors probed following the orthogonal purification Figure 2.3 represent a 
good cross-section of the cofactors identified in Table 2.2.  That is, cofactors 
representing different activities (e.g. mRNA processing, acetyltransferase, H2A.Z 
exchange, etc.) were examined.  As expected, alternate orthogonal purification 
protocols further confirmed the results shown in Figure 2.3. For example, 
orthogonal purification of SREBP-Mediator with an anti-ADA3L antibody resin 
similarly supported an SREBP-Mediator-SAGA interaction (Figure 2.4).   
Although past reports have suggested a direct interaction between human 
 
HADHA, SKIVL2L2, and SnoN did not track with Mediator throughout the orthogonal 
ation 
ruly Mediator-confirming whether cofactors identified in Table 2.2 are t
PU
T
ct
rl
El
ut
io
n
T rl ut
io
n
anti-HADHA
anti-SnoN
Figure 2.3.  Activator binding triggers new Mediator-cofactor interactions.   
Western blots for various cofactors identified from the MudPIT analysis.  Note most, 
but not all, cofactors were confirmed as Mediator-associated in this assay.  LRP130,
purification, suggesting these factors likely interact directly with the SREBP activ
domain and not Mediator. 
Mediator and SAGA (Liu, et al., 2008), these data implicate activator-induced 
structural shifts in promoting and/or stabilizing these interactions.  Not every 
SAGA subunit was identified in Table 2.2, which likely results from its associa
with only a subset of SREBP-Mediator complexes (i.e., SAGA is 
substoichiometric relative to Mediator itself).  Experiments in which Mediator wa
immunodepleted from extracts yielded data that also supported the orthog
purification results; however, such experiments are limited by the fact that 
Mediator cannot be effectively removed in this way, even following six 
tion 
s 
onal 
 Because eight of twelve factors tested positively through the orthogonal 
e of 
potential direct interactions with the activation domain itself (VP16 or SREBP-1a).  
ation of 
A B
immunodepletion steps (See Methods and Figure 2.8). 
purification protocol (Figure 2.3), it is evident that the majority of factors identified 
in Table 2.2 are likely Mediator-associated and are not observed becaus
IN
PU
T
anti-TRRAP
anti-MED1
anti-MED23
ADA3L
IP ELUTION
16X   8X  4X   2X   1X
HeLa NE
SREBP Activator
Affinity Column
0.5M KCl Wash           GSH Elution
                                         (+) Activator
anti-ADA3L or anti-CBP/p300
Immunoprecipitation
0.5M KCl Wash          0.1M Glycine
                                       (+) Activator
anti-MED23 CBP/p300IP ELUTION
Figure 2.4.  Orthogonal purification with ADA3L provides additional confirm
SREBP-Mediator-SAGA interaction.  (A) Purification scheme for the anti-ADA3L 
orthogonal purification from SREBP-Mediator sample.  (B) Western blots probing 
eluted material from ADA3L orthogonal purification for the presence of Mediator 
subunits.  Note that similar results were observed upon orthogonal purification with 
CBP/p300 (lower panel). 
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It remains possible that in some cases a tripartite interaction might occur, in 
which the cofactor might interact simultaneously with the activation domain an
surface exposed within activator-bound Mediator.  In any case, the Mediator-
cofactor interactions identified in Table 2.2 and further validated in
appear to be triggered by activator binding, and, because activator binding 
causes major structural shifts within Mediator, this observation suggests 
activator-induced structural shifts regulate subsequent Mediator-cofactor 
interactions. 
 
d a 
 Figure 2.3 
expose motifs for protein–protein interactions; in agreement with this, additional 
qu
sam tocol 
2.2.3 Distinct Cofactors Associate with SREBP-Mediator vs. VP16-
Mediator. 
 
 The sweeping structural shifts induced by activator-Mediator binding likely 
cofactors were observed to stably associate with Mediator upon activator binding. 
Because SREBP-Mediator adopts a distinct conformational state relative to 
VP16-Mediator, it was hypothesized that distinct cofactors might associate with 
SREBP-Mediator vs. VP16-Mediator.  The data in Table 2.2 support this 
hypothesis, because there are substantial differences between factors 
associated with SREBP-Mediator vs. VP16-Mediator.  To further probe potential 
activator-selective Mediator-cofactor interactions, we completed a series of 
antitative immunoblotting experiments with SREBP- and VP16-Mediator 
ples (Figure 2.5.A).  These samples were purified by using the same pro
35 
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4
3
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MED26
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used for MudPIT analysis (Figure 2.5.B) and the presence/absence of vario
polypeptides was examined by western blot analysis. As shown in Figure 2.5.C, 
(A) Silver-stained acrylamide gels showing glycerol gradient fractions from the 
purification protocols shown in (B).  Mediator-containing fractions are denoted by
red boxes.  (C) Quantitative western blots confirm MudPIT data.  Mediator-associa
factors probed in immunoblotting experiments are shown at left.  Factors show
samples, whereas factors shown in blue font were observed only in the SREBP-Mediator 
sample by MudPIT. 
us 
the data correlate precisely with the MudPIT results shown in Table 2.2.  For 
Figure 2.5.  Distinct cofactors associate with SREBP-Mediator vs. VP16-Mediator.   
 the 
ted 
n in black 
font were observed to be present in both the SREBP-Mediator and VP16-Mediator 
36 
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example, TRRAP, GCN5L, and reptin were identified in both SREBP and VP16-
Mediator samples by MudPIT (Table 2.2).  Each protein was also detected in the 
SREBP-Mediator and VP16-Mediator samples by Western blot analysis, as 
shown in Fig. 2.5.C.  Similarly, the MudPIT data revealed no peptides 
corresponding to ATM, GCN1L1, ADA2B, or ADA3L in the VP16-Mediator 
sample, whereas these proteins were well represented in the SREBP-Mediator 
sample.  In agreement with these data, quantitative western blotting confirmed a 
significant enrichment of these cofactors in SREBP-Mediator fractions (Fig. 
2.5.C), whereas ATM, GCN1L1, ADA2B, and ADA3L were nearly undetectable in 
the VP16-Mediator sample. Note that equivalent amounts of Mediator were 
examined in each experiment, as shown by the Med15 immunoblotting 
experiments (Fig. 2.5.C). Combined with the MudPIT analysis summarized in 
Table 2.2, the data in Figure 2.5 provide strong evidence that Mediator-cofactor 
association can be activator-selective and that this selectivity is conferred by 
distinct activator-bound Mediator structural states. 
 
2.2.4 MudPIT Analysis of CDK8-Mediator. 
contains the Med26 subunit, whereas CDK8-Mediator contains the CDK8 
 
 
 Mediator exists in at least two major forms in human cells: core Mediator 
and CDK8-Mediator.  Core Mediator is devoid of the CDK8 submodule and 
submodule (CDK8, Cyclin C, Med12, and Med13) but lacks Med26 (Taatjes, et
al., 2004).  Thus, Med26 is specific to core Mediator, whereas the CDK8 
26FEB09_Cyclin T_film2_1s
26FEB09_CDK9_film4_3s
26FEB09_CDK9_film5_10s
anti-Rpb1
anti-MED26
anti-MED15
nti-MED1 or anti-Cdk8
Immunoprecipitation
0.5M KCl Wash          0.1M Glycine
                                       (-) Activator
HeLa NE
a
MED1 IP ElutionCDK8 IP Elution
d 
ediator 
er 
owed 
f 
n with Mediator (Knuesel, et 
l., 2009; Naar, et al., 2002). 
 
probing Med1 or CDK8 IP samples for pol II, Med26, or Med15.  Med15 was used as a 
submodule is specific for CDK8-Mediator. Note, however, that the CDK8 
submodule can also exist as a stable entity on its own (Knuesel, et al., 2009).  
Med1 represents a Mediator subunit that is shared between core Mediator an
CDK8-Mediator; thus, Med1 IP samples will represent a mix of CDK8-M
and core Mediator.  As expected, Med26 was not detected in the CDK8 IP 
sample, whereas every other consensus Mediator subunit was identified (Table 
2.1).  Additionally, no pol II subunits were detected in the CDK8 IP sample, 
whereas spectral counts for pol II subunits were abundant in each of the oth
Mediator samples. To verify these results, Med1 and CDK8 IP samples were 
probed for Med26 and the pol II subunit Rpb1, again by using Med15 to 
normalize the two samples (Figure 2.6).  Quantitative western blotting sh
greater than 8-fold enrichment of Med26 and greater than 16-fold enrichment o
Rpb1 in the Med1 IP sample, with no detectable Rpb1, nor Med26, in the CDK8 
IP sample (Figure 2.6).  These results are consistent with past reports that 
indicated mutually exclusive CDK8/pol II associatio
a
A B
32X  16X   8X   4X   2X   1X32X  16X   8X   4X   2X   1X
 
 
Figure 2.6.  Med26 and pol II do not associate with CDK8-Mediator.  (A) Western blots 
Mediator loading control. 
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Gene Alt. name SREBP VP16 CDK8 MED1 Protein MW Description
AFF1 AF4 0 0 7 0 131578 P-TEFb associated factor
AFF4 MCEF 0 0 23 0 127459 P-TEFb associated factor
CCNT1 CycT1 0 0 7 0 80685 P-TEFb subunit
CDK9 0 0 7 0 42778 P-TEFb subunit
TLE3 0 0 25 0 82222 Transducin-like enhanc
RPLP2 0 0 15 0 11665 Ribosomal protein 
YWHAE 14-3-3 epsilon 0 0 7 0 Phosphoserine binding
DDX3X 0 0 5 0 73243 RNA helicase
FLOT1 0 0 5 0 47355 Membrane protein
RPS25 0 0 5 0 13742 Ribosomal protein 
CD44 0 0 4 0 39416 CD44 isoform 12
ACTBL1 0 0 34 0 Actin, beta-like 1
er 3
FOXP4 0 0 10 0 51011 Transcription factor
SMARCB1 INI1/SNF5 0 0 4 0 44141 SWI/SNF subunit
 
 
iate 
d 
The results described here have broad implications for how gene 
expression is regulated in human cells.  First, it is evident that activators serve 
les in controlling gene expression that extend beyond simple recruitment of 
ctors (e.g., Mediator) to the promoter.  In fact, activators appear to regulate 
Mediator function by altering its conformational state, thereby controlling 
s
some cases, cofactor association with Mediator will, in turn, modulate the activity 
of these factors, upon the basis of previous work that demonstrated the GCN5L 
K8 
 
 
 
 Interestingly, MudPIT analysis revealed a set of factors that assoc
specifically with CDK8-Mediator (Table 2.3); these factors were well-represente
in the CDK8 IP sample but not detected in the Med1 IP or activator-bound 
Mediator samples. 
 
2.3 Discussion 
 
Table 2.3  Spectral counts for cofactors observed exclusively in CD
IP samples 
 
ro
fa
ubsequent interactions with other regulatory cofactors.  We anticipate that in 
40 
Sp1
GCRE
Pol II
GTFsTFIID
Mediator
Sp1
GCRE
Pol II
GTFsTFIID
VP16-Mediator
SREBP-Mediator
?
SREBP-1a
VP16
translate into differences in factors 
associated with SREBP-Mediator or 
VP16-Mediator, providing a means f
A A
ac
substrates upon association with Mediator (Knuesel, et al., 2009; Meyer, et al., 
2008).  Second, our results define a mechanism by which the general 
transcription machinery, in particular the Mediator complex, might actually adopt 
ifferent functions in distinct promoter contexts.  Different activators help regulate 
ifferent sets of genes and, intriguingly, different activators induce distinct 
structural shifts within the human Mediator complex (Taatjes, et al., 2002, 2004; 
Meyer, et al., 2010).  Significantly, we 
observe these structural differences 
or 
Mediator to adopt gene-specific functions 
(Figure 2.7).  Thus, these data suggest a 
role for Mediator in orchestrating the 
recruitment and/or exchange of 
coregulatory factors at gene promoters 
and enhancers.  Third, the MudPIT data 
forecast expanded roles for Mediator in 
the control of human gene expression 
(see below). 
 Importantly, numerous Mediator-
cofactor interactions identified in the 
Figure 2.7.  A model tha
the re
study.  Mediator-cofactor interactions 
straightforward means by which 
a spatial and temporal fashion.  Note 
Mediator, trigger interaction with 
etyltransferase and the CDK8 kinase alter their activity toward chromatin 
d
d
 B    B
t summarizes 
sults and implications of this 
do not occur in the activator-free 
state; rather, activator binding signals 
a shift in Mediator structure only when 
engaged at the promoter, providing a 
Mediator activity can be controlled in 
that activator binding not only enables 
Mediator-cofactor interactions, but 
different activators, which induce 
different structural shifts within 
distinct sets of coregulatory factors, 
providing a mechanism by which 
Mediator can adopt activator-specific 
functionality. 
41 
ed 
termined 
 
association with CDK8-Mediator (Meye
identify CBP/p300 and components wit t 
associate with activator-bound Mediato  
activation between Mediator-SAGA or ed in 
past studies (Liu, et al., 2008; Black, et
MudPIT data indicate an enrichment in
the CDK8-Mediator exchange (pontin, 
W  in 
the MudPIT data.  Numerous enzymatic ac
(e.g., GCN5L, CBP/p300, DNA-PK, ATM,
a st r 
(VP16 or SREBP), whereas activator-free Mediator samples contained only 
c t a
s at additional factors were observed to 
associate with Mediator upon activator 
activator-induced structural shifts trigger
MudPITexperiments have been functionally validated with in vitro or cell-bas
experiments. For example, TRRAP and GCN5L associate with activator-bound 
but not activator-free Mediator complexes. Our laboratory previously de
that TRRAP and GCN5L stably assemble within CDK8-Mediator and that this 
“T/G-Mediator” complex phosphorylates S10 and acetylates K14 within histone 
H3, a mark associated with some active genes.  In fact, CDK8 and GCN5L
function synergistically in this context, providing a mechanistic basis for GCN5L 
r, et al., 2008).  The MudPIT data also 
hin the SAGA complex as factors tha
r.  A functional cooperativity in gene
Mediator-CBP/p300 has been describ
 al., 2006).  As another example, the 
 PTEFb (Cyclin-T and CDK9) and AFF4 in 
reptin, p400), and chromatin architecture 
10, HMMR) are strongly represented
tivities also associate with Mediator 
 RECQL5).  These additional Mediator-
 exclusively with activator-bound Mediato
ssociated coregulatory proteins (although 
(Smc1A, Smc3, IQGAP1, nesprin-2, Z
ssociated factors are observed almo
onsensus Mediator subunits withou
ee CDK8 IP data, Table 2.3).  Th
binding provides strong evidence that 
 Mediator-cofactor interactions. The 
biological rationale for this is clear:  A requirement for the activator in directing 
subsequent Mediator-cofactor interactions ensures these interactions are 
controlled in a spatial and temporal fashion.  Indeed, such a strategy prevents 
Mediator-cofactor interactions from occurring when such interactions might be 
unproductive, such as when Mediator is not stably bound to the promoter. 
 Most factors enriched in activator-bound Mediator samples are in fac
specific to SREBP-Mediator; beyond the consensus Mediator subunits, few 
additional factors are observed with VP16-Mediator.  This may reflect the fact 
that VP16 is a viral activator; as such, VP16-Mediator likely evades common 
regulatory strategies by avoiding association with a host of coregulatory prot
The factors identified that associate with SREBP-Mediator are almost certainly 
substoichiometric relative to Mediator itself; that is, these factors likely assoc
with a fraction of SREBP-bound Mediator complexes and should not be 
considered consensus Mediator subunits.  Human SREBP-1a is important for 
expression of several dozen genes (Horton, et al., 2003).  Factors that associate
with SREBP-Mediator (but not VP16-Mediator) might play specialized roles in 
regulating a subset of SREBP target genes, whereas other Mediator-associated 
factors (e.g., CBP/p300) clearly serve more general roles at a wide variety of 
genes.  It will be important in future work to further define potential gene-spe
functions for cofactors that associate with SREBP-Mediator.  These experiments 
will require comparative analyses at many SREBP target genes that corre
factor recruitment and gene expression with activation and nuclear localization
SREBP-1a.  It will also be informative to compare and contrast MudPIT data 
t 
eins.  
iate 
 
cific 
late 
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from 
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Mediator bound to an array of different transcription factors, such as nuclear 
receptors or p53, that induce structural shifts within Mediator distinct from 
SREBP or VP16 (Taatjes, et al., 2004; Meyer, et al., 2010).  Potentially, a subs
of Mediator-associated factors will be unique to p53-Mediator (for example) and
the identity of these factors might provide insight regarding activator-specifi
et 
 
c 
l 
ct 
s.  
s 
nd, 
regulatory mechanisms. 
 As anticipated, MudPIT analysis of CDK8-Mediator yielded no spectra
counts for Med26, pol II, or the pol II-associated factor Gdown1; however, the 
MudPIT data also revealed intriguing differences among pol II and Mediator 
subunits.  Several pol II subunits (Rpb2, Rpb3, Rpb5, Rpb8) were vastly over-
represented in activator-bound versus activator-free Mediator samples.  A distin
role for Med7 in activated transcription was also implicated by the MudPIT data, 
because Med7 was enriched 37-fold in activator-bound Mediator sample
These results might reflect changes in Mediator-pol II interactions that occur 
upon activator-Mediator binding; these subunits may also play key roles in 
activator-dependent transcription.  Additional structural and mechanistic studie
will be required to confirm this, yet it is interesting to note that activator-induced 
structural shifts within Mediator have been linked to activation of promoter-bou
stalled pol II complexes (Meyer, et al., 2010). 
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2.4 Methods 
 
2.4.1 Mediator purification 
 
  Activator-bound Mediator was purified from HeLa nuclear extract using
GST-SREBP-1a (residue
 
s 1–50) or GST-VP16 (residues 411–490) immobilized 
as 
es, 
with 
ed 
 
ning 
teins were eluted with 0.1M 
lycine, pH 2.7. 
Orthogonal purification of activator-bound Mediator samples was 
ompleted by initial purification with GST-SREBP-1a, as described above.  
luted material was then applied to an anti-CDK8 or anti-Med1 resin (similar 
to Glutathione-Sepharose beads (GE Life Sciences).  After binding, the resin w
washed five times with 10 column volumes (CV) 0.5 M KCl HEGN (20 mM Hep
pH 7.6; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40 alternative) and one time 
10 CV 0.15 M KCl HEGN (0.02% NP-40 alternative).  Bound proteins were elut
with 30 mM GSH in elution buffer (80 mM Tris, 0.1 mM EDTA, 10% Glycerol, 
0.02% NP-40, 100 mM KCl) and applied to a 15% to 40% linear glycerol gradient
(in 0.15 M KCl HEG) and centrifuged for 6 h at 55,000 rpm.  Mediator-contai
fractions ( >1.0 MDa) were combined for analysis. 
 Activator-free Mediator was purified using anti-CDK8 or anti-MED1 
antibodies immobilized to Protein A/G Sepharose (Amersham Biosciences).  
Immobilized antibodies were incubated with HeLa nuclear extract at 4 °C.  The 
antibody resin was then washed three times with 20 CV 0.5 M KCl HEGN and 
twice with 20 CV 0.15MKCl HEGN.  Bound pro
G
 
c
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results were obtained with each), washed four times with 20 CV 0.5 M KCl HEGN, 
once with 20 CV 0.15 M KCl HEGN, and eluted with 0.1 M glycine, pH 2.7.  
Wash buffers were supplemented with free GST-SREBP-1a (residues 1–50) to 
nsure activator-bound Mediator complexes remained in the SREBP-bound 
)].  Proteins were 
essed 
30 
 
Promega) and 2 mM CaCl2. 
olume) 
e
conformational state. 
 
2.4.2 MudPIT analysis of Mediator 
 
 Mediator subunits and associated proteins were identified using a 
modified MudPIT procedure (Washburn, et al., 2001) used by the Conaway 
laboratory to identify the consensus Mediator subunits (Sato, et al., 2004).  
Mediator-containing fractions from glycerol gradient-purified samples (typically 
fractions 15 through 17) were combined from four gradients for SREBP and eight 
gradients for VP16 and TCA precipitated [20% (w/v
resuspended with 1% RapiGest SF (Waters) in 0.1 M Tris pH 8.5 and proc
with a modified method (Florens & Washburn, 2006).  Proteins were reduced 
minutes with 5mMTCEP (Pierce) and alkylated 30 minutes in the dark with 10 
mM Iodoacetamide (Sigma).  Suspended proteins were then diluted 4-fold to 
0.25% RapiGest with 0.1 M Tris pH 8.5 and digested overnight at 37 °C with
modified trypsin (
 Digested peptides were acidified with formic acid to 5% (volume/v
and pressure loaded and washed on a 250 µm fused silica capillary column 
packed with 5 cm strong cation exchange resin (Whatman 5 µm Partisphere 
45 
SCX) followed by 2 cm rpC18 (Phenomenex Jupiter 5 µm rpC18).  Loaded 
capillary columns were then connected via a 1 µm Nanofilter (Upchurch) to a
µm × 150 mm rpC18 (LCPackings PepMap 3 µm 100A rpC18).  The assembled
column was attached to an Agilent 1100 HPLC and run at 0.3 µL⁄ min.  Peptid
were fractionated off o
 75 
 
es 
f the SCX with six steps of ammonium acetate (75, 150, 
00, 250, 350, and 500 mM).  Each step was resolved by a 40-minute gradient 
elution  formic acid. 
Eluted peptides were detected using a Agilent MSD XCT—nano ESI 
was 
 
s 
.2) was 
2
 from 3% to 60% acetonitrile with 0.1%
 
(Picotip, New Objective) ion trap mass spectrometer.  Nano-electrospray 
achieved with 1.7 kV and 300–1800 m/z was scanned.  MS/MS spectra were
acquired in a data-dependent fashion from the three most intense parent ion
(1.3 V). Data collection was controlled by the Agilent ChemStation software 
(version A.09.03).  A mascot generic file was created using the Agilent Data 
Analysis software (version 2.2) and Mascot (Matrix Sciences version 2
used to search the human ipi_v3.27 database (Perkins, et al., 1999).  Peptides 
less than seven residues were excluded and a 1% false discovery rate was 
determined by a separate search of the reversed database.  Spectral counts 
were generated by processing identification data with Isoform Resolver as 
described (Old, et al., 2005; Meyer-Arendt, et al., 2011; Resing, et al., 2004). 
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2.4.3 Antibodies 
 
 MED1, CDK8, GCN5L, CBP/p300, ADA3L, LRP130, HADHB (Santa Cruz 
Biotechnology); MED23, TRRAP, GCN1L1, ATM, p400, DNAPK (Bethyl); 
HADHA, ADA2B, Reptin/TIP49B/RUVB2, SMC3, SLIRP, SnoN, SKIV2L2 
(Abcam); Rpb1, MED15, MED26 (lab stocks).  Antibodies against IQGAP1 (Cell
Signaling), SPT3 (Santa Cruz and Abcam), and MMS19 (A
 
bcam) were also 
 to 
ts 
 
 
cannot effectively remove Mediator from a cell extract, thus limiting the 
usefulness of immunodepletion assays.  Why antibodies cannot completely 
remove Mediator from extracts might derive from the fact that Mediator exists in a 
variety of structural states, any of which might mask the epitope for a given 
tested but did not yield reliable results in control experiments. 
 
2.4.4 Mediator “immunodepletion” experiments 
 
 We completed a series of Mediator immunodepletion trials in an effort
further test Mediator-cofactor interactions.  Depletion of Mediator from extrac
should similarly deplete the Mediator-associated cofactors from an SREBP 
affinity purification.  These experiments gave the expected results in that factors
identified to associate with SREBP-Mediator via MudPIT  and orthogonal 
purification (e.g., ATM, GCN5L, ADA2B) were depleted along with Mediator in
SREBP pull-downs from depleted extracts when compared with standard 
extracts.  Over the years, however, we have observed that immunodepletion 
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antibody.  Mediator also interfaces with multiple coregulatory complexes (e.g., 
e CDK8 submodule) and these Mediator-cofactor associations could also block 
; Med1 
.  
t a 
ple, an SREBP-
1a affinity resin binds Mediator to an extent similar to an untreated extract, based 
upon s  Rerunning the 
th
antibody binding to a subset of Mediator complexes within an extract.  Another 
consideration is that few Mediator antibodies are actually effective in an IP
and CDK8 work very well, as revealed by silver staining the bound proteins
Upon completing a tandem immunodepletion using first an anti-Med1 affinity 
resin followed by depletion with an anti-CDK8 antibody resin, it is evident tha
significant amount of Mediator remains in the extract.  For exam
ilver stain analysis and quantitative Western blotting. 
anti-TRRAP
anti-GCN1L1
Depleted MED Control MED
anti-MED1
anti-ADA3L
anti-MED15
anti-ATM
B
anti-GCN5L
anti-ADA2B
anti-MED23
HeLa NE
SREBP-1a
0.5M
KCl Elution
Depleted MED
anti-CDK8 FT
anti-MED1 FT
SREBP-1a
0.5M
KCl ControlMED
Elution
A
HeLa NE
anti-CDK8 FT
anti-MED1 FT
anti-CDK8 FT
anti-MED1 FT
Figure 2.8.  Immunodepletion of Mediator experiment does not completely deplete 
Mediator complexes after a total of six anti-MED1 and anti-CDK8 IPs.  (A) 
Immunodepletion scheme.  (B) Western blots of Mediator and cofactors to show 
degree of immunodepletion. 
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experiment with 6 successive immunodepletion steps (3X anti-Med1, 3X anti -
CDK8) worked to a degree—whereas Mediator was certainly not absent in the 
final antibody IP flow-through fraction (Figure 2.8), it was at least notably 
depleted.  Comparison of the SREBP affinity purifications from the standard vs. 
immunodepleted extract (with silver staining and quantitative Western blot 
analysis) provided the expected results:  In fractions depleted of Mediator, we
observed a corresponding depletion in Mediator-associated factors. 
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of Very Low Abundance Protein Samples 
________________________________________________________________
Chapter 3 
An Improved Proteomics Platform for the Analysis 
 
 
 
 Protein-protein interactions inside the nucleus of a cell are fundamental for 
the overall function of a cell, not to mention the specific inner workings of 
regulating the expression of select genes.  These protein-protein interactions 
assemble metastable complexes which are essential for the dynamic 
associations required for biological functions (Alberts, 1998; Köcher & Superti-
Furga, 2007).  These dynamic associations must be tightly regulated for efficient 
gene expression.  One way to regulate gene expression is to control critical 
protein-protein interactions, and in addition, to maintain low copy numbers of 
critical regulatory cofactors, such as activators, but also entire protein complexes.  
Some of these low copy cofactors can be very difficult to purify and prepare for 
analyses with sufficient recovery to achieve interpretable results.  The mass 
spectrometry-based MudPIT protocol worked well to characterize the protein 
compositions of the purified Mediator complexes in Chapter 2.  The samples 
analyzed were the most concentrated samples that could be purified at the time.  
Significant limitations of the MudPIT protocol were identified throughout the study.  
Sensitivity of the method was primarily limited by the recovery from the 20% (w/v) 
 
3.1 Introduction 
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TCA precipitation which has a lower limit for protein concentration where all or 
most of the protein is precipitated.  When sample protein concentrations are 
below that lim recision 
nd total protein recovery.  TCA and acetone washes may also be insufficient to 
move residual NP-40 required for the Mediator purifications, which may foul the 
r tip.  The first dimension in the MudPIT method is 
trong cation exchange (SCX) which requires salt to elute.  Any salt, even the 
ps.  
ning.  
ns; 
the 
pter 
d 
it, sample recovery is dramatically affected in terms of p
a
re
electrospray (ESI) emitte
s
volatile salts ammonium formate and ammonium acetate dramatically affect the 
current at the nanospray ESI source and shortens the lifespan of emitter ti
Salt residue also collects on the LC pumps, the interface and inside of the ion 
trap mass spectrometer requiring more frequent disassembly and clea
These are practical points identified running samples to generate the data 
provided in Chapter 2.  The eluent passing through the ESI emitter tip affects the 
lifetime of that tip which is required for the production of gas phase peptide io
no ions, no peptides to sequence, no proteins to identify, no data.  Therefore, 
quality of the sample loaded can have a big impact on the quality of the data 
collected. 
 The sample preparation and the LC/MS analysis protocol used in Cha
2 will be discussed and divided into three parts:  (1) precipitation of the purifie
protein samples, (2) proteolysis of protein samples into peptides suitable for 
sequencing in an ion trap mass spectrometer, and (3) the LC/MS/MS analysis 
that separates all the peptides for isolation and sequencing by the ion trap mass 
spectrometer.  This chapter will detail the evaluation of the mass spectrometry-
51 
based MudPIT protocol used in chapter 2, and compare and contrast the protoc
developed to replace it (summarized in Table 3.1) allowing for the analyses o
protein samples of much lower concentration with considerably less 
contamination from the protein purification protocol. 
 
    
ol 
f 
  MudPIT mass spectrometry New Proteomics Platform 
Protein Precipitation 20% (w/v) TCA, 4ºC overnight Insulin, DOC, 20% (w/v) TCA 
    
Protein Proteolysis in solution  30k Filter-Aided Sample Prep 
    
Peptides Loaded Pressure Baume LC Autosampler 
    
Chromatography 2D-LC(SCX/rpC18)/MS/MS 2D-LC(high/low pH rp)/MS/MS 
    
 
 
 3.1.1 Removal of Sample Matrix via Protein Precipitation 
 
 The preparation of low concentration purified protein samples requires the 
removal of sample matrix components nec
Table 3.1  Proteomics Methodologies at a Glance 
essary for the purification of such 
samples, such as detergents (eg NP-40), glycerol (10~35% (vol./vol.)) and salts; 
none are compatible with standard liquid chromatography or ESI mass 
spectrometry.  Protein precipitation is an excellent method for concentrating 
proteins and removing or reducing the sample matrix.  There are a variety of 
common methods for protein precipitation, including the addition of 30~50% 
(weight/ volume) Ammonium Sulfate to salt out protein that can be recovered/ 
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resuspended with native activities.  This method is not generally appropriate for 
very small samples or for mass spectrometry analyses due to the high salt 
concentration added, which would need to be removed.  Furthermore
maintaining native activity is not required for mass sp
, 
ectrometry analyses, 
erefore, denaturing protocols such as the addition of 20% (weight/volume) 
T  (v/v) -20ºC Acetone (and 
variants of these two methods) are very useful for removing, or at least reducing 
salt, glycerol and detergent contamination, as well as concentrating a protein 
s mple prior to proteolysis.  Both of ation protocols have 
been used successfully for the preparation of sample for mass spectrometry. 
 Another variant method for protein precipitation utilizing 20% (w/v) TCA 
detergent deoxycholate (DOC) and the carrier protein 
DOC assists by denaturing the proteins 
induce nucleation of precipitating protein 
th
richloroacetic acid (TCA) at 4ºC or the addition of 80%
a  these denaturing precipit
includes addition of the 
bovine pancreatic insulin (MW 5733.66).  
exposing the hydrophobic cores encouraging nucleation and precipitation.  
Insulin is added as a carrier protein to 
allowing for very high precipitation efficiency with the lowest concentrations of 
protein samples.  This method is suitable for in-gel digestion of proteins for mass 
spectrometry since an acrylamide gel resolves the added insulin.  However, this 
method is not suitable for in solution digestion due to the large amount of insulin 
added to the sample which become an excess contaminant in the mass 
spectrometer. 
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 3.1.2 Proteolysis via Filter-Aided Sample Preparation (FASP) for MS
 
 There are two basic strategies for preparation of protein samples
spectrometry:  (1) in-gel digestion and (2) in solution digestion (as used in th
MudPIT protocol in Chapter 2).  In-gel digestion is a very robust and clean 
sample preparation method, but is limited by low peptide recovery, especially for 
very low concentration samples, and is biased by molecular weight (from the 
percent acrylamide gel used).  Peptide recovery is generally much better with 
solution digestion; however, the sample must be free from contamination 
incompatible with LC/MS (glycerol, detergents, salt, etc.) which can limit the 
 
 for mass 
e 
in 
f 
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 al., 2011a).  When the experiment shown in Figure 3.1.E. was 
ttempted with as 30K MWCO filter using a glycerol gradient purified Mediator, 
o Mediator was detectable by silver staining prior to the addition of trypsin 
ability to purify certain proteins for mass spectrometry analyses. 
 A new method described by the Mann group at the Max Plank Institute o
Biochemistry, called Filter-Aided Sample Preparation (FASP) (Wiśniewski, et al., 
2009) (Figure 3.1), has added another dimension, as a hybrid of an in-gel (u
SDS) and in solution protocols, to preparing protein samples for mass 
spectrometry.  The real key to the FASP protocol is that it allows for proteins to
be solubilized in SDS and urea, a strong detergent and denaturing chaotrope, 
respectively.  This is possible using an ultrafiltration device designed for 
concentrating protein samples, such as a Millipore Microcon or a Sartorius 
Stedim Biotech Vivacon ultra-filtration device, as a proteolysis “reactor” 
(Wiśniewski, et
a
n
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(Figure3.5), suggesting the membrane or plastic of the spin filter bound the 
protein added (see below). 
 The purification protocols for Mediator include the detergent NP-40, which 
is clearly not compatible with LC/MS analysis.  Mediator purifications were 
attempted without NP-40 and with Triton X-100 as an alternative to NP-40, but 
the yields were very poor compared to the inclusion of NP-40.  Therefore, 
removal or replacement of NP-40 in the purification protocol was not feasible for 
robust and reproducible Mediator purifications. 
 This is a major strength of the FASP protocol in that it very effectively 
removes detergents, such as SDS, NP-40 and Triton X-100 (Figure3.2) and likely 
Figure 3.1  Filter-aided sample preparation (FASP) for mass spectrometry (Wiśniewski, 
et al., 2009). 
dilute
away detergents, etc. with 8M urea.  (D) Wash away Urea with ammonium bicarbonate 
 The protocol is (A) solublilize proteins in SDS and reduce with DTT & 
 and wash with 8M Urea.  (B) Alkylate and spin out Iodoacetamide.  (C) Wash 
and add protease.  Digest protein on the filter and spin out peptides.  (E) Acrylamide 
gel of steps A through D. 
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Figure 3.2  FASP removes detergents (Wiśniewski, et al., 2011a). 
(A) Microcon 10/30K filters remove 0.2% (w/v) SDS with four washes of 8M Urea or 
water.  (B) Removal of 0.2% (v/v) Triton X-100, X-114 and NP-40 with four washes of 8M
Urea or water determined by absorbance at 275nm. 
 
m
p n 
s f 
Triton X-100, Triton X-114 and NP-40 (Figure 3.2.B).  The efficient removal of 
detergents by the filter washed with 8M urea allows for no compromises or 
modifications to protein purification protocols. 
 Some controversy (Liebler and Ham, 2009) about the FASP method 
suggested that it was not a “Universal sample preparation method” as the FASP 
authors offered it (Wiśniewski, et al., 2009).  Liebler and Ham suggested the 
method “is useful in some applications” but has “considerable limitations” for 
samples <50ug due to poor peptide recoveries and greater variability.  Liebler 
and Ham offered Table 3.2 which compared the (1) FASP-type spin filter method, 
(2) an in-gel digest from an acrylamide gel run for a short time and (3) 
any other potential contaminants, such as large partially undigested 
olypeptides that would induce spectral noise.  Both the Microcon and Vivco
pin filters were tested with various molecular weight cutoffs for the removal o
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sm g et al., 2005).  In fact, Table 3.2 
shows clearly when 50ug is processed, the spin filter provides the highest 
number of peptide and protein identifications.  However, when 150ng is 
processed the spin filter gives the lowest number of peptides and proteins 
identified.  This is readily explained by Liebler and Ham as non-specific 
protein/peptide binding to the spin filters.  This conclusion is consistent with 
empirical evidence using a CDK8 IP purified Mediator sample with no recovery 
after the input by silver staining (Figure 3.5), mentioned earlier.  It seems likely 
that virtually any membrane or plastic surface has the capacity to non-specifically 
bind some protein and/or peptides.  This is especially difficult to contend with 
when protein concentrations are very low.  For this reason, siliconized, or low-
retention tubes and tips (Fisherbrand) were employed throughout for all of the 
work presented in this thesis.  This strategy was confirmed in a study (Bark and 
Hook, 2007) evaluating tryptic BSA peptides stored in various tubes. 
 
(Liebler and Ham, 2009) 
Table 3.2  Comparison of spin filter, short SDS-PAGE and TFE methods 
olubilzation with trifluoroethanol (TFE), a method developed specifically for 
icro- and nanoscale proteomics samples (Wan
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power of th
first major variable is the protease or multiple proteases used to digest proteins 
into peptides suitable for mass spectrometry analysis.  Sequence coverage has 
been shown to improve nearly 3-fold with multiple proteases compared with 
trypsin only (Swaney, et al., 2010).  There is the practical question of how good is 
good enough?  Swaney, et al., identify an additional 595 proteins on top of 3313 
proteins identified with trypsin only, mostly low abundance factors.  Is it 
necessary to use a panel of proteases and how many analyses are required?  
The biological questions and the goals of a well-thought out experiment should 
lead the way. 
 So now we have a protein sample digested with trypsin, which cleaves the 
carboxyl peptide bond of the basic residues arginine and lysine, so long as there 
is no proline in the carboxyl sequence of the polypeptide.  This is ideal for 
electrospray mass spectrometry which works best for sequencing with positively 
charged peptide ions where the amino-terminus of the peptide is positively 
charged and the basic side chain at the cleaved carboxyl terminus is also 
positively charged, giving at least a plus two charge on the peptide.  Depending 
A practical matter for the analysis of protein samples for mass 
spectrometry is the depth of sequence coverage.  There are many variables that 
contribute to the number of peptides from a given protein that can be identified.  
Two major variables are the protease or proteases employed and the resolving 
e chromatography system up-front of the mass spectrometer.  The 
3.1.3 Orthogonality of Two-Dimensional LC/MS 
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on the sample, there could be hundreds to thousands to tens of thousands of 
eptides that could be identified by the mass spectrometer.  The mass 
eptides 
o 
es 
 
tionates 
states for peptides that can be sequenced by 
oes 
 
(Top) Calculation of normalized retention time for phosphorylase b tryptic digested 
peptides.  pH 10 vs. pH 2.6 rpC18; SCX vs. pH 2.6 rpC18; HILIC vs. pH 2.6 rpC18. 
p
spectrometer has a sampling rate that limits the number of scans for p
and sequencing of each peptide per given amount of time.  If the up-front 
chromatography system can resolve the peptides 
such that the capacity of the mass spectrometer t
collect data is greater than the number of peptid
eluting at any given time, then fewer peptides will
be missed and more complete sequence 
coverage will be the result. 
 The MudPIT protocol was developed to 
extend the peak capacity of a 1D-LC/MS analysis 
with a second dimension SCX which frac
peptides based on the overall charge of the 
peptide.  Unfortunately, the number of charge 
mass spectrometry is limited to 1+, 2+, 3+, 4+ and 
5+, though the majority of peptides sequenced 
are 2+and 3+, and 1+ are excluded, which d
not afford wide variation in separation by the SCX 
dimension.  Today the technology for peptide
separations has advanced with Ultra-High 
Figure 3.3  Normalized retention time plots for two-dimensional orthogonality in LC/MS. 
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Performance Liquid Chromato
high peak capacities in a 1D-LC
(Thermo Scientific) which have
greater resolving power.  This t terize 
much more complex samples w e.  But for older 
technology, such as slower, low resol w 
HPLC systems, enhanced orth
of peptides can produce impres
targeted samples when compa
 There are only a few chr ith 
mass spectrometry.  Reversed
spectrometry in that peptides a
increasing gradient of the volat  
added to maintain a low pH (~2
There are more options in term
phase:  strong cation exchange , 
hydrophilic interaction chromat , which 
d
graphy (UPLC) systems which are capable of very 
 format and LTQ-Orbitrap mass spectrometers 
 greater sensitivity and high mass accuracy for 
echnology allows an investigator to charac
ith greater depth of coverag
Table 3.3  Practical Peak Capacity of 2D-LC (Gilar, et al., 2005) 
1st Dim: pH 10 rp 1st Dim: SCX 1st Dim: HI
2nd Dim: pH 2.6 rp 2nd Dim: pH 2.6 rp 2nd Dim: pH 2.6 rp
Theoretical 2D 
Peak Capacity
13291 5880 9050
LIC
 ution 3D-ion traps and traditional nano-flo
ogonality in the liquid chromatography separation 
sive results with significantly less complex 
red to a UPLC-Orbitrap analysis. 
omatographic separations directly compatible w
 phase is the most well developed for mass 
re loaded in an aqueous buffer and eluted with an 
ile non-polar organic acetonitrile with formic acid
.6), ensuring all peptides are positively charged.  
s of a first dimension fractionation before reversed 
 (SCX), size exclusion chromatography (SEC)
ography (HILIC) and pH 10 reversed phase
eprotonates all acidic residues changing the overall charge state of many 
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p ptides.  An 
 
or 
tly to 
-LC 
 
 
eptides and therefore increases the hydrophilicity of those acidic pe
evaluation of the chromatographic modes listed above (Figure 3.4) was 
performed for one dimension peak capacity as well as two-dimensional peak 
capacity generating a mathematical characterization for chromatographic 
orthogonality (See Table 3.3., Gilar, et al., 2005).  The orthogonality of each 
chromatographic phase was determined in an off-line format since the elution 
from a HILIC column and pH 10 reversed phase would not be compatible with 
reversed phase retention.  Organic modifiers are also frequently added to SCX
separations to prevent non-specific interactions of more hydrophobic peptides.  
This is not a problem for the MudPIT protocol since the acetonitrile elutions f
the reversed phase separation also passed through the SCX column in-line.  An 
alternative to off-line separations is to add another pump (if you have it) and a T-
connector to dilute the organic phase of the first dimension elution sufficien
retain on a reversed phase column. 
 The calculated theoretical peak capacity, or the number of  peaks 
(peptides) that can be separated in a given amount of time, for the three 2D
modes are given in Table 3.3 (Gilar, et al., 2005).  The theoretical peak 
capacities calculated for 2D-LC is lowest for SCX with HILIC and pH 10 reversed
phases giving considerably higher resolving power.  A practical aspect of using 
HILIC or pH 10 reversed phase for a first dimension fractionation is how the 
samples are loaded and eluted.  The samples for a HILIC column is retained at
high organic, sometimes as high as 90% (v/v) acetonitrile.  HILIC is also sensitive 
to salt concentration, therefore samples have to be desalted (additional 
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processing) and suspended in HILIC equilibration buffer.  Elution off the HILIC is 
performed with a polar solvent, such as water often with salt added.  Loa
reversed phase column in aqueous buffer is considerably more convenient in 
terms of the protease digestion buffers.  Elution of a reversed phase colum
occurs with high organic which must be removed (often evaporated) or diluted
retention on a second dimension reversed phase column. 
 
3.2 Results 
 
 The FASP protocol and the pH 10/pH 2.6 reversed phase 2D-LC 
methodology were adapted at the same time, so any individual contributions from
the FASP or 2D-LC/MS were not distinguished.  What really made the FASP 
protocol work so well for very low concentration (<5ug) protein samples is the 
precipitation protocol including insulin
ding a 
n 
 for 
 
.  The carrier protein insulin serves two vital 
on 
vely 
 
 2D-
roles in this new proteomics platform: (1) it allows for very good precipitati
recovery for virtually any purified protein sample, and (2) in large excess of the 
protein sample, binds the membrane and plastics of the spin filter effecti
blocking it from binding the purified protein sample.  The same concept was 
employed by (Wiśniewski, et al., 2011b), where they used carrier substances 
polyethylene glycol or dextrans to clinical protein samples to improve peptide
yields in the low to submicrogram range. 
 The contribution from the pH 10/pH 2.6 reversed phase 2D-LC/MS is likely 
to be marginal if it were directly compared to SCX/pH 2.6 reversed phase
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LC/MS due to the much lower complexity of the purified and therefore targeted 
nature of the samples when compared with a whole cell sample.  What really 
makes the pH 10/pH 2.6 reversed phase 2D better than a SCX/pH 2.6 reverse
phase 2D is the entirely volatile acetonitrile elution with 10mM ammonium 
formate (compared to 500mM ammonium formate to elute the SCX) which is 
significantly better for the LC pumps with little to no observ
d 
ed effect on the ESI 
mitter tips.  The only drawback and what may have prevented this method from 
ooner, is that a third LC pump is required to dilute the first 
imension elution with aqueous formic acid buffer through a T-connector.  The 
ase 
 
 in 
 
 
e 
ation with Carry Bernecky in the 
e
being put in place s
d
autosampler loads the sample onto the first dimension pH 10 reversed ph
column and then a binary pump step elutes the peptides off which is diluted by 
the third pump for trapping on a reversed phase C18 trapping column which is
washed and placed in-line with a nano-flow reversed phase column in virtually 
the same configuration as a 1D-LC/MS system. 
 The results presented in this chapter will show the significant difference
protein recovery with the insulin/TCA precipitation protocol and some of the first
samples used to test the new proteomics platform including a CDK8 IP and a
glycerol gradient purified SREBP-1a-Mediator, which will both be directly 
compared with data from Chapter 2 generated using the MudPIT protocol.  Th
absolute sensitivity of the methodology will be demonstrated by Mediator and 
RNA Pol II samples processed in collabor
Taatjes lab. 
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 3.2.1 Comparison of Protein Precipitation Protocols. 
 
 A more dilute glycerol gradient Mediator fraction was used to compare the
protein precipitation protocols adding: (1) 20%(w/v) TCA at 4ºC, (2) 80%(v/
Acetone at-20ºC, and (3) Insulin, DOC and 20%(w/v) TCA at 4ºC.  All samples 
were processed identically except for the precipitation.  Figure 3.4 clearly shows
the enhanced recovery of Mediator polypeptides with the insulin, DOC, TCA 
method compared to the other two methods.  When a more concentrated samp
was used with the various precipitation methods, there was no advantage with 
the insulin, DOC, TCA method.  The threshold of protein concentration require
for good recoveries with 20% (w/v) TCA at 4ºC or 80% (v/v) -20ºC Acetone were
not determined, but these are simpler methods tha
don’t require adding anything to the sample if you 
have a sufficient pro
 
v) 
 
le 
d 
 
t 
tein concentration for good 
sulin is 
 
pic) 
sample recovery. 
 Insulin contamination in the mass 
spectrometry analysis is not a problem when the 
spin filters are used for the FASP protocol.  In
two polypeptides connected by disulfide bonds.  
During the processing, those disulfide are reduced
and alkylated leaving two peptides (monoisoto
Figure 3.4  Protein Precipitation of glycerol gradient purified Mediator fractions.  
Insulin, DOC, TCA clearly gives superior recovery compared with TCA alone and 
Acetone. 
64 
2338.98 Da and 3398.68 Da (prior to alkylation), of which the excess is removed 
y the urea washes. 
s 
 
.  
ed 
 spin filter and washed with 8M 
u ris pH 8.5 
SP 
 
and loaded directly onto the pH 10 first 
n-line” 
b
 
3.2.2 CDK8-IP from HeLa Nuclear Extract 
 
 The first sample successfully tested with the FASP and high/low pH 2D-
LC methodology was a CDK8 IP from HeLa nuclear extract (NE).  This IP wa
chosen for the fast, reasonably clean good Mediator yield the purification 
provided and it was a good representative sample.  CDK8-bound proteins were
eluted with 0.1M Glycine, pH 2.75 and 
precipitated with the insulin, DOC, TCA method
The pellet was suspended with 4% SDS and 
reduced, then diluted with 8M urea and 
alkylated.  The suspended protein was add
to a Microcon
rea, then 2M urea, both with 0.1M T
(Figure 3.5).  This is a deviation from the FA
protocol reported by Wiśniewski, et al., 2009, in 
that ammonium bicarbonate is replaced with
2M urea and 0.1M Tris pH 8.5 for the trypsin 
digestion.  Peptides are spun out of the filter 
Figure 3.5  Filter-Aided Sample 
P
C
reparation (FASP) samples from 
DK8 IPs. dimension reversed phase column for “o
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desalting and fractionation.  All data was processed with a 1% false discovery 
rate threshold. 
 The sample scale was half for this test of the new proteomics platform 
FASP/ mple used for MudPIT due 
 the expected increase in sensitivity from the insulin precipitation protocol 
 
r 
this 
 
 
sample with the FASP/high-low m
likely lower abundance factors, some which may be non-specific, but in fact 
many fit together with other factors in the dataset. 
factors that make up and associat b 
(P-TEFb) were identified only in the CDK8 IPs (Table 3.5).  These factors were 
a low analysis plus additional P-TEFb 
associated factors were also identified (Table 3.5).  Many of the additional 
high-low reversed-phase compared with the sa
to
primarily.  Shown in Table 3.4, as expected, nearly twice the total proteins were
identified from over four times the number of peptides.  The number of Mediato
peptides were nearly double, though two fewer subunits were identified in 
n=1 comparison, indicating replicates are absolutely required for best coverage. 
ified from approximately half of the 
ethod compared with the MudPIT.  Most are 
 In the MudPIT analysis, 
e with positive transcription elongation factor 
There are 138 additional proteins ident
lso identified with the FASP/high-
%singl
eptides proteins peptides subunits p
1614 160 499 29 55.3%
Total Mediator (33) e
CDK8 IPs IPs /1mL NE p eptide
MudPIT 12X
FASP/high-low 6X 3687 298 785 27 54.5%
Table 3.4  CDK8 IPs comparing MudPIT and FASP/high-low at 1% FDR 
66 
Table 3.5  Additonal P-TEFb-Associated cofactors identified in CDK8 
IP using FASP/high-low method. 
M FASP/high-low Gene Prot MW Description
7 6 CDK9 42778 CELL DIVISION PROTEIN KINASE 9
7 19 CCNT1 80685 CYCLIN-T1
1 CCNT2 81029 CYCLIN-T2
23 61 AFF4 127459 AF4/FMR2 FAMILY MEMBER 4
5 HEXIM1 40623 PROTEIN HEXIM1
1 SUPT5H 121000 TRANSCRIPTION ELONGATION FACTOR SPT5
1 TCEB1 12473 TRANSCRIPTION ELONGATION FACTOR B1
1 TCERG1 123901 TRANSCRIPTION ELONGATION REGULATOR
3 RNMT 57725 mRNA CAP GUANINE-N7 METHYLTRANSFERASE
udPIT
6 AFF1 132252 AF4/FMR2 FAMILY MEMBER 1
14 ELL2 72324 RNA POLYMERASE II ELONGATION FACTOR ELL2
1 SF3A3 58849 SPLICING FACTOR 3A SUBUNIT 3
1 SFRS1 27745 SPLICING FACTOR. ARGININE/SERINE-RICH 1
1 SFRS2IP 128875 SFRS2-INTERACTING PROTEIN
1 SFRS6 39587 SPLICING FACTOR. ARGININE/SERINE-RICH 6
8 KHSRP 73115 KH-TYPE SPLICING REGULATORY PROTEIN
8 BAT1 50679 SPLICEOSOME RNA HELICASE BAT1
10 PABPC1 70671 POLYADENYLATE-BINDING PROTEIN 1
Spectral Counts
3 SFRS3 19330 SPLICING FACTOR. ARGININE/SERINE-RICH 3
cofactors have a single spectral count and by themselves are not very compelling 
identifications, however, when combined together as they are in Table 3.5, a 
trend begins to emerge.  A hypothesis could be developed that a new function for 
e 
r 
Ps 
an be 
CDK8-Mediator is a regulator of transcription elongation and mRNA processing.  
The association of P-TEFb and CDK8 is further explored in Figures 3.6 to Figur
3.8.  The association of CDK8 with mRNA processing factors has been furthe
investigated in the Taatjes Lab with additional mass spectrometry of CDK8 I
from various column fractions, however, this data is beyond the scope of this 
thesis.  The data presented in Table 3.5 goes most directly to show how 
improvements in the methodology have expanded the hypotheses that c
generated from the same sample, in this case a CDK8 IP. 
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 To further validate the P-TEFb association with CDK8, P-TEFb was 
probed by quantitative western blotting to compare directly the CDK8 and MED1
IP elutions for P-TEFb subunits CDK9 and Cyclin-T1 along with Mediator 
subunits (Figure 3.6).  The western blot data confirms the mass spectrometry 
that P-TEFb is detected most prominently in the CDK8 IP and not in the M
(Donner, et al., 2010).  The cofactor Brd4, a bromodomain-containing protein th
binds acetylated chromatin, has been reported to regulate P
Figure 3.6  P-TEFb associates with CDK8-Mediator. (A) Silver stain of CDK8 and MED1 
immunoprecipitates (IPs). Mediator and associated cofactors were immunoprecipitate
from HeLa nuclear lysates using antibodies specific for CDK8 (CDK8-Mediator and 
immunoblotting of IP elutions shows CDK9 and cyclin T1 enriched in the CDK8 IP. 
d 
CDK8 submodule) and MED1 (core Mediator and CDK8-Mediator).  (B) Quantitative 
(Adapted from Donner, et al., 2010) 
 
in 
ED1 IP 
at 
-TEFb (Yang, et al., 
68 
2005) and associate with the Mediator complex (Jang, et al., 2005), was included 
 
 
Figure 3.7  P-TEFb associates with two distinct CDK8 complexes, CDK8-Mediator and 
the CDK8 four protein subcomplex. (Adapted from Donner, et al., 2010)  
in Figure 3.6, though it was not identified in any of the mass spectrometry 
datasets. 
 Next, to see how far P-TEFb would track with CDK8 in an extensive
endogenous CDK8 purification scheme, various column fractions from a previous
study in the Taatjes lab purifying endogenous CDK8 subcomplex and CDK8-
Mediator (Knuesel, et al., 2009) were probed for P-TEFb (figures 3.7).  Both the 
CDK8 subcomplex and CDK8-Mediator appears to interact with P-TEFb In this 
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experiment.  A second independent experiment was performed, again with pre-
existing fractions, probing for P-TEFb in Superose 6 gel filtration fractions of 
HeLa nuclear extract (Figure 3.8).  The original purpose of this experiment was to 
quantitate and compare the abundance of CDK8-Mediator and the CDK8 
subcomplex.  There appears to be more CDK8-Mediator than CDK8 submodule 
Figure 3.8  Superose 6 column fractions from ammonium sulfate precipitated HeLa 
nuclear extract input probing CDK8 and P-TEFb.  There appears to be more CDK8-
Mediator than CDK8 subcomplex, but P-TEFb associates with both complexes. 
in this experiment, but P-TEFb als
c
 The MudPIT data generated a new hypothesis for a functional interaction 
between CDK8 and P-TEFb.  This was further validated (Figures 3.6 through 3.8) 
with biochemical purification and western blotting showing P-TEFb appears to 
interact with both CDK8-Mediator and the CDK8 subcomplex.  The new 
FASP/high-low method has expanded the list of transcription elongation-
associated cofactors associating with CDK8 to include mRNA capping, splicing 
and polyadenylation/termination cofactors. 
 
o appears to again interact with both 
omplexes. 
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 3.2.3 SREBP-1a-Mediator from HeLa Nuclear Extract 
 
 Another direct comparison of the MudPIT method with the FASP/high-low 
method comes from an affinity purification of Mediator using the activation 
domain of the activator SREBP-1a.  Data in Table 3.6 show that with 
approximately 10% of the sample used for the MudPIT analysis in Chapter 2, 
m in 
identifications.  Nearly twice the Mediator peptides were identified with the 
, 
 
ore than four times the peptides were identified for an additional 464 prote
FASP/high-low method for the same number of Mediator subunits identified.  
Other cofactors identified in the MudPIT analysis included SMC1A and SMC3
components of the Cohesin complex, which holds sister chromatids together 
during mitosis.  NIPBL was also identified, which is known to be a Cohesin
Table 3.6  GST-SREBP-1a pulldowns from HeLa nuclear extract 
comparing MudPIT and FASP/high-low at 1% FDR 
GST %single
GST-SREBP-1a pulldowns peptides proteins peptides subunits peptide
Mu
Total Mediator (33)
dPIT 10X 1685 128 1065 32 55.3%
FASP/high-low 1X 8046 592 2025 32 50.5%
MudPIT FASP/high-low Gene Prot MW Description
6 62 SMC1A 143233 STRUCTURAL MAINTENANCE OF CHROMOSOMES 1A
URAL MAINTENANCE OF CHROMOSOMES 3
4 44 NIPBL 304344 NIPPED-B-LIKE PROTEIN
5 RAD50 138432 DNA REPAIR PROTEIN
2 STAG2 145751 STROMAL ANTIGEN 2
6 24 SMC3 141542 STRUCT
Spectral Counts
Table 3.7  GST-SREBP-1a pulldowns identify Cohesin 
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loa es for 
extract and mouse embryonic stem (mES) cells (Figure 3.9).  Once again the 
Mu , in this case 
ding factor.  The FASP/high-low method identified 10-times the peptid
Figure 3.9  Cohesin (Smc3) and Nipbl co-purify with mediator. The input fractions and 
immunoprecipitated eluate (IP eluate) were examined by western blot and silver 
staining. (Kagey, et al., 2010) 
SMC1A and NIPBL and 4-times the peptides for SMC3 (Table 3.7).  Two 
additional Cohesin-associated cofactors were also identified, RAD50 and STAG2. 
 To further validate the association of Cohesin with SREBP-1a-Mediator, 
the orthogonal purification used in Chapter 2 was employed with HeLa nuclear 
dPIT data predicted a functional protein-protein interaction
between the Mediator complex and the Cohesin complex.  This data, along with 
other data (Kagey, et al., 2010) provide evidence that Mediator and Cohesin 
protein complexes cooperate in the formation of enhancer-promoter DNA loops. 
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 3.2.4 Sub-Microgram Scale VP16-Mediator and RNA Pol II. 
 
 The entire RNA Pol II complex (12 subunits) and highly purified VP16-
Mediator were combined with recombinant TFIIF (2 subunits) to generate a 
highly purified VP16-activator- Mediator- Pol II-TFIIF complex to obtain a 
structure using electron microscopy (Bernecky, et al., 2011).  To thoroughly 
characterize the compositions of the purified RNA Pol II and the purified VP16-
Mediator, the FASP/high-low method was used.  Since both the Pol II and 
Mediator samples are highly purified, there was not much sample to spare, 
therefore, approximately 1 ug of VP16-Mediator and approximately 2 ug of RNA 
Pol II were digested into peptides with the FASP protocol.  The resulting peptides 
were split for technical replicates and stored at -80ºC until analysis.  Each 
approximately 1 ug.  This sample scale was sufficient for identification of all 
analyses (Table 3.8).  Technical replicates were required for all subunits to be 
identified for both RNA Pol II and Mediator and will be the precedent for further 
Mediator analysis was approximately 500ng and each Pol II analysis was 
twelve subunits of RNA Pol II and all expected Mediator subunits from replicate 
peptides proteins peptides subunits peptides subunits
Mediator rep1 1046 74 53 6 612 26
Total VP16-MediaRNA Pol II
RNA Pol II rep1 3471 140 2660 10 6 4
RNA Pol II rep2 3204 157 2022 12 5 4
Mediator rep2 1225 91 59 6 635 28
tor
Table 3.8  RNA Pol II (~1ug) and VP16-Mediator (~0.5ug) totals. 
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analyses.  The total number of spectral counts for RNA Pol II and Mediator are 
etween half and two-thirds the total number of spectral counts, indicating that 
 
d 
b
they are indeed the major components of those samples.  Analytical technical
replicates are fairly good for this scale of sample, but sequence coverage an
subunit coverage is exceptional, which was the ultimate goal of these 
experiments (Table 3.9 and Table 3.10). 
 
 
Table 3.9  RNA Pol II spectral counts and subunit sequence coverage. 
Sequence
3 4 0 0 POLR2F 14478 8.7%
24 44 1 3 POLR2H 17143 46.7%
0 11 0 0 POLR2L 7645 16.4%
10 12 6 6 subunits
RNA Pol II VP16-Mediator
rep1 rep2 rep1 rep2 Gene Prot MW Coverage
1191 678 30 37 POLR2A 217206 29.2%
488 509 9 5 POLR2B 133897 32.7%
182 171 3 7 POLR2C 31441 25.5%
262 202 1 1 POLR2D 16311 40.8%
110 78 9 6 POLR2E 24551 29.5%
243 236 0 0 POLR2G 19294 35.5%
72 72 0 0 POLR2I 14523 67.2%
0 1 0 0 POLR2J 14131 14.2%
85 16 0 0 POLR2K 7004 14.2%
2660 2022 53 59 sums
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Table 3.10  Mediator spectral counts and subunit sequence coverage. 
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Sequence
2 0 96 88 MED1 168478 1
0 3 50 68
0 0 21 28
RNA Pol II VP16-Mediator
 
 
rep1 rep2 rep1 rep2 Gene Prot MW Coverage
4.4%
MED14 160607 11.3%
MED23 157114 4.3%
0 0 55 55 MED24 110305 7.9%
0 0 49 34 MED16 96793 8.3%
1 0 91 84 MED15 86753 13.6%
0 0 16 15 MED25 84389 5.8%
3 0 11 6 MED27 35432 3.5%
0 0 10 9 MED8 32819 19.9%
0 0 20 23 MED4 29745 17.0%
0 0 6 9 MED6 29298 24.8%
0 0 11 8 MED7 27245 15.0%
0 0 12 12 MED18 24453 11.1%
0 0 13 11 MED29 23473 26.7%
0 0 23 29 MED20 23222 16.0%
0 0 9 11 MED22 22221 21.4%
0 0 1 1 MED19 20431 4.5%
0 1 5 14 MED30 20277 14.0%
0 0 8 18 MED9 16403 11.6%
0 1 28 29 MED31 15805 26.7%
0 0 13 12 MED10 15688 9.6%
0 0 4 2 MED21 15564 12.5%
0 0 1 3 MED11 13129 23.9%
6 5 612 635 total Mediator peptides
4 4 26 28 total Mediator subunits
0 0 19 27 MED17 72876 10.3%
0 0 40 39 MED26 65446 18.3%
 
 
 
3.3 Discussion 
 
 
 
 
  
  
Mass spectrometry is a powerful technique with enormous discovery 
potential.  The MudPIT method was an elegant way to expand the peak capacity 
of 1D-LC/MS systems with 3D ion trap mass spectrometers.  Furthermore, it has 
been applied successfully to characterize the consensus Mediator subunits (Sato, 
et al., 2004) as well as many other experiments.  However, developing the 
MudPIT method on the hardware available, and consequently running many 
samples (Chapter 2) uncovered many technical challenges (Table 3.11).  Some 
of these challenges could be worked around, and some simply could not. 
Table 3.11  Pros or Cons of Proteomics Methodologies. 
MudPIT mass spectrometry New Proteomics Platform 
  
Protein Precipitation poor recovery for low/very low Very good recovery for all 
  concentration protein samples concentrations of samples 
    
Protein Proteolysis NP-40 residual may exist with in solution digestion 
FASP is very good for removal 
of detergents 
    
LC/MS Analysis Requires Single-Use Columns Commercial Columns can be 
   used for extended time 
  Salt Elutions NOT compatible  
  with pumps, ESI emitters, MS Requires Three HPLC pumps 
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 Ultimately the MudPIT method simply was not rugged enough in my hands 
r reliable and consistent analyses.  The high pH-low pH reversed phase 2D-LC 
eparation detailed here was a logical progression of the concept for expanding 
e peak capacity of a system for greater depth of sample coverage.  Many of the 
chnical issues affecting the robustness of the MudPIT method were addressed 
ith implementation of the high-low pH 2D method.  It is much more reliable and 
bust than the MudPIT method ever was.  I don’t wake up in the middle of the 
ight to drive 30 minutes to check on the mass spectrometer anymore; I don’t 
eed to! 
The more critical modification to the proteomics platform was clearly the 
daptation of the FASP protocol for preparing protein samples for mass 
pectrometry.  In combination with a TCA precipitation protocol using a carrier 
rotein, the method became virtually universal.  The poor recovery of low 
bundance samples was addressed by two points, (1) complete precipitation 
covery, and (2) effectively blocking the spin filter with a peptide that can flow 
rough the filter limiting non-specific adsorption of sample protein/peptides.  The 
otential of this method was enormous for a lab that routinely purifies very small 
mount of very low abundance proteins.  Analyzing samples of this nature is not 
hat would not have been feasible for analysis can now be 
haracterized in depth.  This will be demonstrated in Chapters 4 where activators 
a 
fo
s
th
te
w
ro
n
n
 
a
s
p
a
re
th
p
a
trivial.  Many samples t
c
that give low Mediator yields, p53 and p65/RelA/NFKb, are analyzed and dat
presented.  It simply would not have been possible to analyze these samples 
with the MudPIT method used in Chapter 2. 
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3.4 Methods 
 
3.4.1 CDK8 and SREBP-1a Mediator purifications 
 
 CDK8-Mediator was purified using anti-CDK8 antibodies (Santa Cruz) 
mobilized to Protein A/G Sepharose (Amersham Biosciences).  Immobilized 
ntibodies were incubated with HeLa nuclear extract at 4 °C.  The antibody resin 
.5 M KCl HEGN 
d twice with 20 CV  pro .1M 
lycine, pH 2.7. 
SREBP-1a-Me a T-
es h
 After e  
lumes (CV) 0.5 M K H 7.6; 0.1 mM EDTA; 10% 
lycerol; 0.1% NP-40 alternative) and one time with 10 CV 0.15 M KCl HEGN 
(0.02% NP-40 alternative).  Bound proteins were eluted with 30 mM GSH in 
elution buffer (80 mM Tris, 0.1 mM EDTA, 10% Glycerol, 0.02% NP-40, 100 mM 
KCl)and applied to a 15% to 40% linear glycerol gradient (in 0.15 M KCl HEG) 
and centrifuged for 6 h at 55,000 rpm.  Mediator-containing fractions (>1.0 MDa) 
were combined for analysis. 
 
 
im
a
was then washed three times with 20 column volumes (CV) 0
an  0.15MKCl HEGN.  Bound teins were eluted with 0
G
 diator was purified from HeL  nuclear extract using GS
SREBP-1a (residu  1–50) immobilized to Glutat ione-Sepharose beads (GE 
Life Sciences).  binding, the resin was wash d five times with 10 column
vo Cl HEGN (20 mM Hepes, p  
G  
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3.4.2 Sample preparation and mass spectrometry analyses of 
Mediator and RNA Pol II complexes. 
 
 Purified Mediator complex (~1ug) and RNA Pol II complex (~2ug) fraction
were precipitated at 4ºC using 20%(w/v) TCA, 0.067mg/mL insulin and 
0.067%(w/v) deoxycholate. Precipitated protein pellets were washed twice with
20ºC Acetone and air dried. Proteins were trypsin digested using a slightly
modified Filter-Aided Sample Prep (FASP) protocol (Wiśniewski, et al., 2009).
Briefly, protein pellets were suspended with 4%(v/v) SDS, 0.1M Tris pH 8.5, 
10mM TCEP and incubated 30m ambient to reduce disulfides. Reduced proteins 
were diluted with 8M Urea, 0.1M Tris pH8.5 and iodoacetamide was added to 
10mM and incubated 30m in total darkness. Reduced and alkylated proteins 
were then transferred to a Microcon YM-30 spin concentrator and washed twice 
with 8M Urea, 0.1M Tris pH 8.5 to remove SDS. Three washes with 2M Urea, 
0.1M Tris pH8.5 were performed then trypsin and 2mM CaCl
s 
 -
 
 
 
  Peptides were desalted online 
 a Phenomenex Jupiter C18 (5µm 300Å; 0.25 x 150mm) 
olumn using a two dimensional LC/MS/MS method (Agilent 1100). Seven steps 
of incre mM ammonium 
rmate pH10, 4% acetonitrile and B: 10mM ammonium formate pH10, 65% 
 a 
t 
2 were added and 
incubated approximately 2 hours in a 37ºC water bath. Digested peptides were
eluted and acidified with 5%(v/v) formic acid.
and fractionated with
c
asing acetonitrile (3, 6, 9, 12, 16, 20 and 100%B; A: 20
fo
acetonitrile) at 5µL/minute eluted peptides for a second dimension analysis on
Dionex Acclaim PepMap C18 (3µm 100Å; 0.075 x 150mm) running a gradient a
79 
0.2µL/minute from 5 to 25% B in 100 minutes for steps one through six and 10 to 
30% B in 100 minutes for step seven (A: 4% acetonitrile & B: 80% acetonitrile,
both with 0.1% formic acid pH~2.5). PepMap eluted peptides were detected with
an Agilent MSD T
 
 
rap XCT (3D ion trap) mass spectrometer. 
 
 
ore 
 
ein 
 All spectra were searched with Mascot v2.2 (Matrix Sciences) against the
International Protein Index (IPI) database version 3.65 with two missed 
cleavages and mass tolerances of m/z ±2.0 Da for parent masses and ±0.8 Da
for MS/MS fragment masses. Peptides were accepted above a Mascot ion sc
corresponding to a 1% false discovery rate (1% FDR) determined by a separate
search of a reversed IPI v3.65 database. Peptides were then filtered and prot
identifications were assembled using in-house software as described (Meyer-
Arendt, et al., 2011; Resing, et al. 2004).
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________________________________________________________________ 
Chapter 4 
Future Directions 
Activator-Specific Mediator Interactomes 
________________________________________________________________
 
 
 
 
 
 
ee 
 
e 
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4.1 Introduction 
 
 The Mediator complex is a large protein complex that integrates signals 
from DNA-binding transcription activators.  The activator SREBP-1a was shown 
to induce a structural shift in the Mediator complex compared to an activator-fr
Mediator complex.  A mass spectrometry-based methodology was used to 
characterize the protein-protein interactions that were associated with each 
structural state.  The results were that activator-bound Mediator contained an
additional subset of cofactors compared with activator-free Mediator.  The next 
question to address is whether distinct activators can regulate the recruitment of 
distinct cofactors.  To test this idea the family of three SREBP isoforms, 1a, 1c 
and 2, are used to purify Mediator complexes for comparison.  To further test th
idea, additionally activators used to purify Mediator are p53 and p65/RelA (NFkB)
 
4.1.1 Activator-Specific Mediator Interactome 
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 Distinct activators have been demonstrated to produce unique stable 
structural conformations of the Mediator complex (Taatjes, et al., 2002 and 
Figure 4.1).  The functional relationship of this structural dynamics may be for the
spatial and temporal regulation of protein-protein interactions that are activato
and/or gene-specific.  Evidence for this co
 
r 
ncept is provided in Chapter 2 
comparing the activators SREBP-1a and VP16.  Figure 4.1 shows the unique 
conformations of the Mediator complex when bound to activators SREBP-1a, 
VP16, p53 and the RNA Pol II CTD.  It is expected that when Activator-bound 
Figure 4.1  Activator-Specific Mediator Conformations.  Distinct structures of activator-
bound Mediator regulate protein-protein interactions. Activators VP16, SREBP-1a, p53 
and the CTD of RNA Pol II.  What might the structures of SREBP-1c, SREBP-2 and 
p65/RelA look like? 
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Mediator structures are rendered for SREBP-1c, -2 and p65/RelA that they also 
will be distinct.  These unique structural conformations can elegantly control the 
functional output of a specific gene.  By comprehensively characterizing the 
protein interactome of each activator-Mediator complex, new hypotheses can be 
enerated regarding activator-specific cofactors required for the proper regulation 
r target genes.  Mass spectrometry is an ideal technology for characterizing and 
in interaction networks (Köcher T and Superti-Furga, 
007; Gingras, et al., 2007; Choudhary and Mann, 2010).  Improvements in the 
 
IT 
r.  
 
 
ypotheses for SREBP, p53 and p65/RelA gene activation.  Some interesting 
future 
 
g
o
comparing protein-prote
2
proteomic platform have enabled the analyses of purified protein complex 
samples such as these performed here.  All of the additional activator complexes
analyzed in this chapter have reasonably low protein yields and concentrations, 
which would have been difficult if not impossible to process using the MudP
methodology from Chapter 2.  In fact p53 was previously attempted with 
insufficient recovery of protein to even attempt to put on the mass spectromete
The use of insulin as a carrier protein gives very high recovery of purified protein
and the adaptation of the FASP sample preparation allows for the removal of the 
added insulin and efficient purification of target protein tryptic peptides ready for
mass spectrometry. 
 The data presented here is the discovery phase for the generation of new 
h
directions derived from the data will be offered. 
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4.1.2 Sterol Regulatory Element-Binding Proteins (SREBP) 
 
 Sterol regulatory element-binding proteins (SREBP) are DNA binding 
transcription activators that regulate fatty acid and cholesterol metabolism 
(Eberle, et al., 2004; Horton, et al., 2003; Brown and Goldstein, 1997).  Tw
genes encode three SREBP isoforms called SREBP-1a, SREBP-1c and SREB
2 (Goldstein, et al., 2002).  SREBP-1a and SREBP-1c are splice isoforms 
differing by only the first exon of the gene srebf1.  SREBP-2 is a product of the
o 
P-
 
phospholipids.  SREBP-2 is an activator 
a  
for genes that synthesize cholesterol 
nd the LDL receptor (Horton, et al., 2003).  Due to the clear and distinct genes
srebf2 gene.  SREBPs are unique membrane proteins of the endoplasmic 
reticulum (ER) in that they are transcription activators.  A protein called SREBP 
cleavage-activating protein (SCAP) acts as a sterol sensor that binds SREBPs to 
escort them from the ER to the Golgi where the amino-terminal (~500 amino 
acids) is cleaved and released to translocate to the nucleus to bind the sterol 
response elements at the promoters of target genes (Goldstein, et al., 2002).  All 
three isoforms target the MED15 subunit of the Mediator complex (Yang, et al., 
2006).  If overexpressed, all SREBP isoforms activate genes involved in 
cholesterol and fatty acid synthesis and the low-density lipoprotein (LDL) 
receptor (Horton, et al., 2003).  The different isoforms do have selective roles, 
however.  SREBP-1a is a potent activator for all SREBP-responsive genes, 
where SREBP-1c is less potent (Horton, et al., 2003), though both are activators 
for genes that process fatty acids and the assembly of triglycerides and 
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that are activated by SREB-1a/-1c and SREBP-2 (Horton, et al., 2003), it is 
proposed that there may be subsets of activator-specific cofactors recruited to 
the Mediator complex that are involved in activator-specific gene activation.  
Therefore, the activation domains of each SREBP isoform will be used to bind 
the Mediator complex and any isoform-specific cofactors that may be involved in 
the regulation of gene activation for a comprehensive protein interactome 
analysis of each. 
 
4.1.3 p53 and p65/RelA 
 
 The transcription activators p53 and p65/Rel A, part of the NFkB complex 
(Perkins, 2007; Hayden and Ghosh, 2004,2008), are also compared more for 
convenience, though, it does make for an interesting comparison.  These
activators regulate many target genes.  Both activators bind the Mediator 
complex (p53: Ito, et al., 2003; Meyers, et al., 2010; and p65/RelA: Näär, et al., 
1999) through their activation domains to activate transcription at target gene 
promoters.  The tumor suppressor p53 is often thought of as a sensor for the 
overall health of a ce
 
ll directing cell fate to senescence or apoptosis (Kruse and 
 
wever, how these 
anscription factors activate transcription at the promoter is still less clear.  This 
hapter is not for in-depth molecular mechanisms of gene activation for p53 or 
Gu, 2009).  NFkB, on the other hand, is often thought of as tumor-promoting and 
anti-apoptotic transcription factor (O'Shea and Perkins. 2008).  Many modes of
regulation are known for these transcription factors, ho
tr
c
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p65/R
ypothesis that unique activators, when bound to Mediator, initiate distinct 
te the 
 
.D), 
l 
elA (or SREBPs either), but rather to provide data that supports a 
h
protein-protein interactions. 
 
4.2 Results 
 
 To test the hypothesis that distinct transcription activators can regula
protein-protein interactions for the activator-bound Mediator complex, a mass 
spectrometry based approach was applied again to comprehensively 
characterize activator-specific protein complexes, as in Chapter 2, but with 
additional activators.  Improvements in the proteomics platform, detailed in 
Chapter 3, which have significantly improved the sensitivity and depth of 
coverage for protein analyses have made these particular activator-bound 
Mediator purifications amenable to analyses. 
 
4.2.1 Mediator-Bound SREBP (-1a, -1c, -2) 
 
 GST-fusions of the activation domains for SREBP-1a, SREBP-1c and 
SREBP-2 were used as bait for pulldowns from HeLa nuclear extract (Figure
4.2.A & B).  The protein complexes bound were gently eluted with glutathione 
(GSH) (Figure 4.2.C) and applied to a 2 mL glycerol gradient (Figure 4.2
which resolves much of the free fusion-activator and smaller activator-bound 
cofactors, such as the acetyltransferase coactivators p300/CBP (~300kD glycero
86 
gradient fractions 5-9, Figure 4.2.D), from the Mediator-containing fractions 
(~1+MDa, boxed in red, Figure 4.2D).  One and two glycerol gradient 
purifications were used for SREBP-1a, while four to eight glycerol gradient 
purifications were combined for SREBP-1c and SREBP-2 for a single mass 
Figure 4.2  Sterol Regulatory Element-Binding Protein (SREBP) family of transcription 
activators bind Mediator.  (A) Diagram of activation domain fusion proteins.  (B) 
stained acrylamide gels of SREBP purifications.  What other cofactors are recruited that
are activator-specific? 
Purification scheme.  (C) GSH elutions/inputs for SREBP-1a, -1c and -2.  (D) Silver 
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spectrometry analysis.  Four replicates were completed for each isoform 
SREBP.  All 12 analyses were combined for 71,789 total peptides identified
5465 unique peptides which 
of 
; 
identified 1535 total proteins with 50.55% single 
eptide protein identifications.  It is common to accept protein identifications with 
ides, however, the stringent bioinformatics data processing 
rovides a probability of 1% False Discovery Rate (1%FDR).  Many of the single 
g 
r 
P-
and 
ts for 
e Mediator complex and Table 4.3 
r RNA Pol II.  Consistent with greater activation potency (Horton, et al., 2003), 
SREB o-fold more 
p
two unique pept
p
peptide identifications may be noise, or low level contamination, or they can be 
cofactors that are parts of complexes with more peptides per identification fillin
in protein sub-complexes that are sub-stoichiometric. 
 The total peptide & protein identifications, the total number of Mediato
peptides and the total number of RNA Pol II peptides identified in this SREB
Mediator study by replicate are given in Table 4.1. The Mediator complex 
RNA Pol II are predominant constituents of each purification.  Spectral coun
individual subunits are given in Table 4.2 for th
fo
P-1a pulls down 2 to 4-fold more Mediator and more than tw
88 
total peptides 8046 8335 5087 5211 4639 3411 5160 5755 6988 7377 6014 5
total MEDIATOR proteins 32 32 32 32 30 29 28 25 30 19 28
total RNA Pol II proteins 9 9 9 9 8 6 9 8 8 5 7
replicate 1 2 3 4 1 2 3 4 1 2 3 4
SREBP-1a SREBP-1c SREBP-2
technical technical technical biological biologicalbiological
766
total proteins 592 602 302 350 317 332 413 522 693 598 432 404
total MEDIATOR peptides 2025 2151 1592 1555 843 883 491 457 598 169 498 483
27
total RNA Pol II peptides 235 261 266 255 123 143 98 119 133 37 95 67
7
replicates replicatesreplicates replicates replicates replicates
Table 4.1  SREBP Isoforms Spectral Counts totals for all protein 
identifications, Mediator and RNA Pol II. 
RNA Pol II by total spectral counts compared with SREBP-1c and SREBP-2
from four to eight-fold fewer gradients. The silver stained acrylamide g
glycerol gradient fractions confirm at a glance a clear difference in total prot
pulled down as well as total Mediator polypeptides (red box in Figure 4.2.D). 
, 
els of 
eins 
 Not 
all Mediator subunits were identified in each replicate, but between four 
replicates, all Mediator subunits were identified with each SREBP isoform (Table 
4.2).  Subunits of RNA Pol II are provided in Table 4.3. 
 After comparing the 
Mediator and RNA Pol II 
composition of the purifications 
from each SREBP isoform, a list of 
exclusive cofactors was also 
generated for each.  We do not 
propose that each cofactor 
exclusive to one isoform or another 
is truly exclusive, since it could just 
be below the limit of detection for 
the other two isoforms, but rather 
the data presents an opportunity to 
test new hypotheses.   
 Factors exclusive to 
le 4.4.  SREBP-1a are given in Tab
Vinculin (VCL) is a cytoskeleton 
Table 4.2  SREBP Spectral Counts for 
Mediator by subunit. 
SREBP-1a SREBP-1c SREBP-2 Gene Prot MW
765 269 219 MED12 243081
88 36 32 MED12 or MED12L
0 0 1 MED12L 240032
516 247 108 MED13 239318
3 0 0 MED13 or MED13L
300 91 34 MED13L 242602
709 262 215 MED1 168478
555 127 68 MED14 160607
379 103 33 MED23 156194
480 167 188 MED24 110305
260 64 29 MED16 96793
468 148 121 MED15 86753
89 44 18 MED25 84389
314 67 114 MED17 72876
135 57 35 MED26 65446
31 17 12 CDK19 56802
91 53 49 CDK8 or CDK19
4 0 0 CDK8 53284
218 71 32 MED27 35432
76 47 17 CCNC 33243
88 48 41 MED8 32819
197 102 57 MED4 29745
25 5 5 MED6 28425
197 101 53 MED7 27245
21 3 1 MED19 26273
26 4 3 MED18 24453
120 24 51 MED29 23473
95 25 23 MED20 23222
106 78 41 MED30 20277
51 MED21 15564
122 57 15 MED11 13129
47 11 1 MED28 19520
107 20 11 MED22 16480
138 34 47 MED9 16403
79 21 9 MED31 15805
100 24 14 MED10 15688
374 247
89 
protein and it is completely 
unknown why it would associ
with the activation domain of 
SREBP-1a.  TXLNA and 
KLRAQ1 are coiled-coil dom
containing proteins, again with 
unknown function for SREBP-1a
activation.  CIAO1 is an adapter protein involved in pre-mRNA processing that 
associates with FAM96B and MMS19.  These cofactor
ate 
ain-
 
s may make up a sub-
P-
SREBP-1a SREBP-1c SREBP-2 Gene Prot MW
403 218 120 POLR2A 217206
270 93 85 POLR2B 133897
57 25 19 POLR2C 31441
30 13 12 POLR2G 19294
55 37 22 POLR2H 17143
89 64 38 POLR2D 16311
57 15 16 POLR2I 14523
2 0 0 POLR2K 7004
37 15 20 POLR2E 24551
17 3 0 POLR2J 14131
Table 4.3  SREBP Spectral Counts for 
RNA Pol II by subunit. 
stoichiometric subcomplex that binds SREBP-1a-Mediator.  A number of SREB
1a exclusive cofactors appear to be involved in vesicle trafficking.  Since 
SREBPs are membrane-bound in the ER prior to cleavage and activation, 
BP1a BP1c BP2 Gene Prot MW Protein descriptor
46 0 0 VCL 116722 ISOFORM 1 OF VINCULIN.
37 0 0 TXLNA 61891 ALPHA-TAXILIN.
35 0 0 KLRAQ1 88314 ISOFORM 1 OF KLRAQ MOTIF-CONTAINING PROTEIN 1.
Table 4.4  SREBP-1a Exclusive Cofactors. 
33 0 0 CIAO1 37840 PROBABLE CYTOSOLIC IRON-SULFUR PROTEIN ASSEMBLY PROTEIN CIAO1.
32 0 0 GOLGA4 261140 ISOFORM 1 OF GOLGIN SUBFAMILY A MEMBER 4.
.
MAIN-CONTAINING PROTEIN 1.
IMILAR TO SYNTAXIN-BINDING PROTEIN 2.
18 0 0 KLC4 68640 ISOFORM 1 OF KINESIN LIGHT CHAIN 4.
18 0 0 PDDC1 19539 ISOFORM 3 OF PARKINSON DISEASE 7 DOMAIN-CONTAINING PROTEIN 1.
17 0 0 SEPTIN8 49814 ISOFORM 2 OF SEPTIN-8.
16 0 0 CXorf15 60586 GAMMA-TAXILIN.
16 0 0 NCOA2 159157 NUCLEAR RECEPTOR COACTIVATOR 2.
15 0 0 TRIM11 52774 ISOFORM 1 OF TRIPARTITE MOTIF-CONTAINING PROTEIN 11.
15 0 0 LRRFIP2 82171 ISOFORM 1 OF LEUCINE-RICH REPEAT FLIGHTLESS-INTERACTING PROTEIN 2.
13 0 0 VPS33B 70615 VACUOLAR PROTEIN SORTING-ASSOCIATED PROTEIN 33B.
12 0 0 PKN2 112035 SERINE/THREONINE-PROTEIN KINASE N2.
12 0 0 RFWD3 85094 RING FINGER AND WD REPEAT DOMAIN-CONTAINING PROTEIN 3.
12 0 0 KLC1 65310 ISOFORM A OF KINESIN LIGHT CHAIN 1.
11 0 0 TSSC4 34285 ISOFORM 1 OF PROTEIN TSSC4 (FRAGMENT).
10 0 0 KLC2 68935 KINESIN LIGHT CHAIN 2.
10 0 0 MMS19 115749 CDNA FLJ55586. HIGHLY SIMILAR TO MMS19-LIKE PROTEIN.
10 0 0 TANC1 202192 ISOFORM 1 OF PROTEIN TANC1.
10 0 0 UBA5 44863 UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME 5.
29 0 0 FAM96B 17663 UPF0195 PROTEIN FAM96B.
24 0 0 PIBF1 89805 ISOFORM 1 OF PROGESTERONE-INDUCED-BLOCKING FACTOR 1
22 0 0 GCC1 87811 GRIP AND COILED-COIL DO
21 0 0 STXBP2 67700 CDNA FLJ54775. HIGHLY S
90 
perhaps association of these cofactors is suggestive of a feedback mechanism
Cofactors involved in the ubiquitin proteasome system are also represented i
the SREBP-1a exclusive factors list.  TRIM11 and RFWD3 are E3 ubiquitin 
ligases and UBA5 an ubiquitin activating enzyme.  In fact, TRIM11 has been 
reported to interact with MED15 to induce its degradation in the regulatio
TFG-beta signaling (Ishikawa, et al., 2006).  TRIM11 has also been shown to 
regulate the neurogenic transcription factor Pax6 also th
.  
n 
n of 
rough the ubiquitin 
2008).  RFWD3 has been reported to 
plex when phosphorylated by ATM/ATR to prevent p53 
n 
(Fu, et al., 2010). 
 A very interesting subcomplex of cofactors exclusive to SREBP-1c is 
given in Table 4.5.  This subcomplex consists  
UVRAG which make up a vacuolar protein so l., 
2010).  This vacuolar sorting complex is know
proteasome system (Tuoc and Stoykova, 
bind the MDM2-p53 com
degradation, which is unique since all other E3 ligases promote p53 degradatio
 of PIK3C3, BECN1, PIK3R4 and
rting complex (Behrends, et a
n to regulate phosphoinositide 
BP1a BP1c BP2 Gene Prot MW Protein descriptor
0 57 0 PIK3C3 101549 PHOSPHATIDYLINOSITOL 
0 28 0 SHCBP1 75660 SHC SH2 DOMAIN-BINDING PROTEIN 1.
0 26 0 DLAT 68997 COMPONENT OF PYRUVAT
0 17 0 BECN1 51896 BECLIN-1.
0 15 0 PIK3R4 153103 PHOSPHOINOSITIDE 3-KINASE REGULATORY SUBUNIT 4.
0 15 0 SF3B4 44386 SPLICING FACTOR 3B SUB
0 10 0 FAM192B 29152 RCNIP30 (FRAGMENT).
0 8 0 UVRAG 78151 UV RADIATION RESISTANCE-ASSOCIATED GENE PROTEIN.
0 8 0 MIS12 24140 PROTEIN MIS12 HOMOLOG.
0 8 0 FEM1B 70264 PROTEIN FEM-1 HOMOLOG .
0 5 0 PRDX3 27693 THIOREDOXIN-DEPENDENT PEROXIDE REDUCTASE. MITOCHONDRIAL.
0 4 0 C15orf23 35438 PUTATIVE TRAF4-ASSOCIA
0 4 0 MRPS21 10742 28S RIBOSOMAL PROTEIN S2
0 4 0 C14orf43 114989 UNCHARACTERIZED PROT
0 4 0 ELF2 62711 ISOFORM 1 OF ETS-RELAT
0 4 0 PYGL 97149 GLYCOGEN PHOSPHORYL
0 4 0 TUFM 49875 TU TRANSLATION ELONGATION FACTOR. MITOCHONDRIAL PRECURSOR.
3-KINASE CATALYTIC SUBUNIT TYPE 3.
EDEHYDROGENASE COMPLEX. MITOCHONDRIAL.
UNIT 4.
 B
TED FACTOR 1.
1. MITOCHONDRIAL.
EIN C14ORF43.
ED TRANSCRIPTION FACTOR ELF-2.
ASE. LIVER FORM.
Table 4.5  SREBP-1c Exclusive Cofactors. 
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s toph oze, 
2009).  Autophagy is the cellular process of recy
d
degradation.  In addition to recycling proteins, autophagy catabolizes diverse 
cellular energy sources (Simonsen and Tooze, 2
dynamic feedback between degradation and cel
reasonable premise for a functional interaction o
s 
 in 
s 
identified have unknown function and a number are involved in vesicle trafficking, 
c It is possible many of these 
ignaling to facilitate the assembly of an au agosome (Simonsen and To
cling defective proteins by 
elivery to the lysosome for 
009).  This recently discovered 
lular metabolism provides a 
f SREBP and a component of 
the autophagy interaction network.  It seems likely the PIK3C3 subcomplex bind
directly to the activation domain of SREBP-1c, however, if it did bind Mediator
a SREBP-1c-bound state, it could directly connect transcription regulation and 
autophagy. 
 SREBP-2 exclusive cofactors are given in Table 4.6.  Many cofactor
collecting them in autophagosomal vesicles for 
ytosolic enzyme and mitochondrial cofactors.  
cofactors have multiple functionalities with their nuclear functions unknown.  In 
this case, there may be many new hypotheses to test.  One trend is the number 
of motor proteins and more so with SREBP-2, the number of proteasome 
subunits.  Ubiquitin-proteasome signaling has been connected to transcription 
regulation (Hammond-Martel, 2011) but many of the exact molecular mechanism 
are yet unknown.  A cofactor not included in Table 4.6 found significantly 
enriched in SREBP-2 is KIAA0368, or ECM29.  A single spectral count was 
identified in both the SREBP-1a and SREBP-1c purifications, which is why it did 
not appear on the exclusive cofactors list (Table 4.6), while 319 spectral counts 
92 
were identified in SREBP-2.  This is a significant number of spectral counts 
compared with ~1700 for the 2 MDa Mediator complex.  ECM29 is a HEAT 
repeat protein that interacts with the 26S Proteasome.  Genome-wide two hy
and mass spectrometry identified molecular motors, endosomal components a
ubiquitin-proteasomal factors such as ECM29-interacting proteins (Gorbea, et
2010).  If ECM29 interacted with SREBP-2-Mediator, it would be another 
example of transcription regulation coupled with ubiquitin-proteasome signal
but also provide hypotheses for new molecular mechanisms of SREBP gene 
activation which includes molecular motors and endosomal processing. 
brid 
nd 
 al., 
ing, 
BP1a BP1c BP2 Gene
0 0 78 PYCR2
Prot MW Protein descriptor
33637 PYRROLINE-5-CARBOXYLATE REDUCTASE 2.
0 0
0
0 0 26 ALDH3A2 54848 ISOFORM 1 OF FATTY ALDEHYDE DEHYDROGENASE.
.
0 0 23 ENO1 47169 ISOFORM ALPHA-ENOLASE OF ALPHA-ENOLASE.
0 0 17 MYO9B 243401 MYOSIN IXB ISOFORM 1.
0 0 14 RNF160 205177 ZINC FINGER PROTEIN 294.
0 0 14 ATP5B 56560 ATP SYNTHASE SUBUNIT BETA. MITOCHONDRIAL.
0 0 14 PPIA 18012 PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A.
RFACE ANTIGEN HEAVY CHAIN.
0 EMIA GROUP D2 PROTEIN.
0 0 13 PSMB5 28480 PROTEASOME SUBUNIT BETA TYPE-5.
0 0 13 P4HA2 60902 ISOFORM IIB OF PROLYL 4-HYDROXYLASE SUBUNIT ALPHA-2.
0 0 13 PSMA2 25899 PROTEASOME SUBUNIT ALPHA TYPE-2.
0 0 12 PAICS 47958 PHOSPHORIBOSYLAMINOIMIDAZOLE CARBOXYLASE.
0 0 12 POLDIP3 48102 SIMILAR TO POLYMERASE DELTA-INTERACTING PROTEIN3.
0 0 11 TELO2 91747 TELOMERE LENGTH REGULATION PROTEIN TEL2 HOMOLOG.
0 0 11 PFKM 81776 ISOFORM 2 OF 6-PHOSPHOFRUCTOKINASE. MUSCLE TYPE.
0 0 11 PSMA1 29556 ISOFORM SHORT OF PROTEASOME SUBUNIT ALPHA TYPE-1.
0 0 11 INTS6 100390 ISOFORM 1 OF INTEGRATOR COMPLEX SUBUNIT 6.
0 0 11 GALNT2 64733 POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 2.
0 0 11 CD97 81743 ISOFORM 2 OF CD97 ANTIGEN.
0 0 10 IPO7 119517 IMPORTIN-7.
0 0 10 COPB1 107142 COATOMER SUBUNIT BETA.
0 0 10 SPG20 72833 SPARTIN.
0 0 10 PML 97551 ISOFORM PML-1 OF PROBABLE TRANSCRIPTION FACTOR PML.
0 0 10 HNRNPR 70943 HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN R.
0 0 10 HSPH1 92116 ISOFORM BETA OF HEAT SHOCK PROTEIN 105 KDA.
0 0 10 GANAB 109438 ISOFORM 2 OF NEUTRAL ALPHA-GLUCOSIDASE AB.
0 0 10 PFN1 15054 PROFILIN-1.
0 0 10 MRPS34 25650 28S RIBOSOMAL PROTEIN S34. MITOCHONDRIAL.
Table 4.6  SREBP-2 Exclusive Cofactors. 
49 MCM2 101896 DNA REPLICATION LICENSING FACTOR MCM2.
0 31 RRP12 143702 ISOFORM 1 OF RRP12-LIKE PROTEIN.
0 0 25 TFRC 84871 TRANSFERRIN RECEPTOR PROTEIN 1.
0 0 23 ARFGEF1 208767 BREFELDIN A-INHIBITED GUANINE NUCLEOTIDE-EXCHANGE PROTEIN 1
0 0 19 NCL 65962 HIGHLY SIMILAR TO NUCLEOLIN.
0 0 19 NOC4L 58468 NUCLEOLAR COMPLEX PROTEIN 4 HOMOLOG.
0 0 17 MYBBP1A 148855 ISOFORM 1 OF MYB-BINDING PROTEIN 1A.
0 0 16 SCFD1 72380 SEC1 FAMILY DOMAIN-CONTAINING PROTEIN 1.
0 0 14 SLC3A2 57945 ISOFORM 2 OF 4F2 CELL-SU
0 13 FANCD2 166462 ISOFORM 1 OF FANCONI AN
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 4.2.2 Mediator-Bound p53 & p65/RelA 
 
 GST-fusions of the activation domains for p53 and p65/RelA were use
bait for pulldowns from HeLa nuclear extract (Figure 4.3.A & B).  The protein 
complexes bound were gently eluted with glutathione (GSH) (Figure 4.3.C) and 
applied to a 2 mL glycerol gradient (Figure 4.3.C), which resolves much of th
free fusion-activator and small activator-bound cofactors, such as the 
acetyltransferase coactivators p300/CBP (~300kD glycerol gradient fractions 5-9, 
Figure 4.3.C), from the Mediator-containing fractions (~1+MDa, boxed in red, 
d as 
e 
Figure 4.3  p53 and p65/Rel A bind Mediator.  (A) diagram activation domain fusion 
proteins.  (B) Purification scheme used.  (C) Silver stained acrylamide gels of p53 and 
p65/RelA-Mediator purifications.  What other cofactors are recruited that are activator-
specific? 
94 
Figure 4.3.C).  Four glycerol gradient purifications were used for p53, while eight 
g or p65/RelA for a single mass 
total peptides 4529 4752 2957 3059
total MEDIATOR proteins 29 32 30 29
total RNA Pol II peptides 92 113 50 63
p53 p65/RelA
technical replicates technical replicates
total proteins 527 517 321 343
total MEDIATOR peptides 540 605 481 433
total RNA Pol II proteins 8 9 6 7
replicate 1 2 1 2
Table 4.7  p53AD and p65/RelA Spectral Count totals for all protein 
identifications, Mediator and RNA Pol II. 
lycerol gradient purifications were combined f
spectrometry analysis.  Two replicates were completed for each p53 and 
p65/RelA.  A 1% False Discover Rate (1%FDR) was again applied.  Many of the 
single peptide identifications may be noise, or low level contamination, or they 
can be cofactors that are parts of complexes with more peptides per identification 
filling in protein sub-complexes that are sub-stoichiometric. 
 Total protein and peptide identifications, total Mediator and total RNA Pol 
II spectral counts are given in Table 4.7.  The totals for p53 are very close to 
those from SREBP-1c and SREBP-2, while p65/RelA total are lower.  The same 
type of experiment with p65/RelA was reported with three cell types, THP1, 
Jurkat and HeLa (Owen, et al., 2005).  A couple of major difference were Owen 
et al., 2005, (1) did not run GST elutions over a glycerol gradient, and (2) they 
eluted with samples with loading buffer and prepared samples for mass 
spectrometry using in-gel digestion.  This approach would increase the likelihood 
95 
of non-specific identifications and also 
M
would limit overall sensitivity of the 
analysis.  This is most easily 
demonstrated by the number of Mediator 
subunits identified by Owen, et al., 2005, 
which was nine, while we identified all 31 
subunits (Table 4.8).  Total protein 
identifications are not compared due to 
the completely different methods used 
for each analysis which cannot account 
for contaminating cofactors. 
 All expected Mediator subunits 
were identified for both p53 and p65/RelA (Table 4.8).  Total spectral counts for 
ediator in p53 and p65/RelA were quite close.  Nine of twelve RNA Pol II 
p53
36 25 MED17 72876
5 9 CDK19 56802
37 13 CDK19 or CDK8
3 0 CDK8 53284
21 24 MED27 35432
13 31 CCNC 33243
26 29 MED8 32819
53 44 MED4 29745
4 2 MED6 28425
16 22 MED7 27245
6 5 MED19 26273
2 1 MED18 24453
33 27 MED29 23473
9 16 MED20 23222
25 11 MED30 20277
1 12 MED28 19520
17 21 MED22 16480
4 9 MED9 16403
11 13 MED31 15805
8 5 MED10 15688
33 31 MED21 15564
36 4 MED11 13129
1145 914 Total Spectral Counts
p65 Gene Prot MW
134 89 MED12 243081
30 28 MED13L 242602
106 72 MED13 239318
107 74 MED1 168478
112 62 MED14 160607
38 31 MED23 156194
112 95 MED24 110305
21 23 MED16 96793
63 56 MED15 86753
11 14 MED25 84389
12 16 MED26 65446
Table 4.8  p53AD and p65/RelA 
Mediator S
ea
pectral Count totals for 
ch subunit. 
Table 4.9  p53AD and p65/RelA 
RNA Pol II Spectral Count totals for 
each subunit. 
p53 p65 Gene Prot MW
100 48 POLR2A 217206
39 15 POLR2B 133897
6 7 POLR2C 31441
16 29 POLR2D 16311
7 8 POLR2E 24551
7 2 POLR2G 19294
18 3 POLR2H
11 1 POLR2I
1 0 POLR2J 14131
205 113 Total Spectral Counts
17143
14523
96 
subunits were identified with p53 and eight with p65/RelA.  Only with a purified 
RNA Pol II sample have all twelve Pol II subunits been ident
Figure 4.4  Venn diagram of all identifications for p53 and p65/RelA. 
ified. 
nd 
 
1) 
PB2 
 Total protein identifications were higher for p53 than p65/RelA, despite 
very similar numbers for Mediator.  This may suggest somewhat more 
promiscuous binding of the p53 activation domain relative to p65/RelA.  Figure 
4.4 shows a Venn diagram of total protein identifications found in both p53 a
p65/RelA as well as unique protein identifications.  When p53 exclusive cofactors
are assembled, there is a trend in the number of adapter proteins (AP2 and AP
found.  These adapter proteins are found in clathrin-coated vesicles.  CO
and COPA, also exclusive to p53 are coatamer proteins that regulate the 
97 
p53 p65 Gene Prot MW Protein descripto
248 0 RIF1
98 
r
274466 TELOMERE-ASSOCIA
72 0 MRPS25 20116 28S RIBOSOMAL PROTEIN S25. MITOCHONDRIAL
41 0 LANCL1 45283 LANC-LIKE PROTEIN 1
40 0 AP2A1 105370 AP-2 COMPLEX SUBUNIT ALPHA-1
37 0 CALU 38051 CDNA FLJ31776 FIS. HIGHLY SIMILAR TO CALUMENIN
33 0 AP2B1 104553 AP-2 COMPLEX SUBUNIT BETA
30 0 KIF14 186492 KINESIN-LIKE PROTEIN KIF14
24 0 AP2M1 49655 AP-2 COMPLEX SUBUNIT MU
22 0 RPS4X 29598 40S RIBOSOMAL PROTEIN S4. X ISOFORM
19 0 PPP1CB 37187 SER/THR-PROTEIN PHOSPHATASE PP1-BETA CATALYTIC SUBUNIT
19 0 WAPAL 132946 WINGS APART-LIKE PROTEIN HOMOLOG
17 0 REPIN1 63575 REPLICATION INITIATOR 1
15 0 AP2S1 12417  AP-2 COMPLEX SUBUNIT SIGMA
15 0 LACTB 60694 SERINE BETA-LACTAMASE-LIKE PROTEIN. MITOCHONDRIAL
15 0 TAF4 110114 TRANSCRIPTION INITIATION FACTOR TFIID SUBUNIT 4
14 0 MRPS26 24212 28S RIBOSOMAL PROTEIN S26. MITOCHONDRIAL
14 0 MRPS6 14227 28S RIBOSOMAL PROTEIN S6. MITOCHONDRIAL
14 0 TAF5 86830 TRANSCRIPTION INITIA
13 0 TCP1 60344 T-COMPLEX PROTEIN 1 S
13 0 YTHDC2 160248 PROBABLE ATP-DE
12 0 CCT3 60463 CHAPERONIN CONT
12 0 MRPS22 41280 28S RIBOSOMAL PROTEIN S22. MITOCHONDRIAL
15 0 AP1B1 20505 AP-1 COMPLEX SUB
11 0 COPB2 102487 COATOMER SUBUNIT BETA
11 0 CUL4A 87680 CULLIN-4A
11 0 HAUS1 31863 HAUS AUGMIN-LIKE
11 0 HCFC1 208732 HOST CELL FACTOR
11 0 KDM3B 191611  LYSINE-SPECIFIC D
11 0 PELP1 124868 PROLINE-. GLUTAMICACID-. LEUCINE-RICH PROTEIN 1
11 0 POLDIP3 48102 HIGHLY SIMILAR TO PO
11 0 PRPF6 106925 PRE-MRNA-PROCESSIN
11 0 RPS6 28681 40S RIBOSOMAL PR
10 0 COPA 138346 COATOMER SUBUNI
TED PROTEIN RIF1
TION FACTOR TFIID SUBUNIT 5
UBUNIT ALPHA
PENDENT RNA HELICASE YTHDC2
AINING TCP1. SUBUNIT 3
UNIT BETA-1.
 COMPLEX SUBUNIT 1
EMETHYLASE 3B
LYMERASE DELTA-INTERACTING PROTEIN 3
G FACTOR 6
OTEIN S6
T ALPHA
transport of proteins between the ER an
vesicles.  There is a significant represen
transport both with and without clathrin.  W
interactions are non-specific contaminan ractions will 
require biochemical validation and a det nation of specificity for p53-Mediator 
mere-
binding protein in yeast regulating telomere length.  In humans, however, the 
rs. Table 4.10  p53AD exclusive cofacto
d the Golgi with non-clathrin-coated 
tation of cofactors involved in vesicle 
hether these protein-protein 
ts or bona fide functional inte
ermi
or p53-alone.  The cofactor Rif1, also specific to p53 with 248 spectral counts, is 
worth noting due to the rather high number of spectral counts.  Rif1 is a telo
p53 p65
Table 4.11  p65/Rel A exclusive cofactors. 
Gene Prot MW Protein descriptor
GSTM3 26560 GLUTATHIONE S-TRANSFERASE MU 3
CTSA 54466 LYSOSOMAL PROTECTIVE PROTEIN
GLB1 76075 BETA-GALACTOSIDASE
JUP 62616 HIGHLY SIMILAR TO JUNCTION PLAKOGLOBIN
GRPEL1 24279 GRPE PROTEIN HOMOLOG 1. MITOCHONDRIAL
PSMA7 27887 PROTEASOME SUBUNIT ALPHA TYPE-7
SF3B4 44386 SPLICING FACTOR 3B SUBUNIT 4
NFS1 50196  CYSTEINE DESULFURASE. MITOCHONDRIAL
KLHDC2 46099 KELCH DOMAIN-CONTAINING PROTEIN 2
SETD8 42890 HISTONE-LYSINE N-METHYLTRANSFERASE SETD8
TADA2A 51496 TRANSCRIPTIONAL ADAPTER 2-ALPHA
CDK9 42778 CELL DIVISION PROTEIN KINASE 9. CATALYTIC SUBUNIT OF P-
HEXIM1 40623 NEGATIVE REGULATOR OF P-TEFb
PSMD4 40737 26S PROTEASOME NON-ATPASE REGULATORY SUBUNIT 4
SAPS1 103139 PROTEIN PHOSPHATASE 6 REGULATORY SUBUNIT 1
KNTC1 250749 KINETOCHORE-ASSOCIATED PROTEIN 1
PLAUR 36978 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR
SP1 80693 TRANSCRIPTION FACTOR SP1
0 62
0 22
0 14
0 14
0 12
0 10
0 10
0 9
0 8
0 8
0 8
0 6 TEFb 
0 6
0 6
0 6
0 5
0 5
0 5
ortholog of Rif1 was found to associate only with telomeres with DNA damage 
(Silverman, et al., 2004).  At DNA double-strand breaks, human Rif1 was shown 
to associate with the DNA damage kinase ATM for the overall protection against 
DNA damage (Silverman, et al., 2004; Wang, et al., 2009).  ATM is a kinase 
known to target p53 for activation during DNA damage (Shiloh, 2006; Kruse and 
Gu, 2009), and is also identified in all SREBP, p53 and p65/RelA-Mediator.  We 
Mediator-specific orthogonal purification with western blotting (Figure 2.5).  
transcription-related cofactors such as the mRNA splicing factor SF3B4, the 
have also shown that ATM associates with SREBP-1a-Mediator using a 
Future directions should include biochemical validation in terms of an orthogonal 
purification testing both adapter proteins and Rif1. 
 Cofactors identified that are exclusive to p65/RelA (Table 4.11) include 
lysosomal, cytosolic enzymes, and mitochondrial cofactors, along with 
histone methyltransferase SETD8, the elongation-associated kinase CDK9 and 
99 
100 
its tivator SP1.  It seems, however, 
somewhat unlikely that these cofactors generally involved in transcription could 
be truly specific to p65/RelA, but certainly garner further investigation. 
 
4.3 Discussion 
 
 To test the hypothesis that the Mediator complex can regulate protein-
protein interactions in an activator-dependent fashion, an improved proteomics 
platform (Chapter 3) was used to comprehensively characterize the composition 
of various activator-bound Mediator complexes.  Since all activators used in 
these studies were GST-fusions, each activator can serve as a control for any 
other activator allowing for a qualitative comparison.  Mediator and RNA Pol II 
specific spectral counts are given and can be compared for each activator in 
terms of Mediator/Pol II yields.  Other Associated cofactors identified exclusively 
with distinct activators were also assembled from the datasets. 
 A compelling idea comes from the association of the Beclin3-PIK3C3 
subcomplex involved in autophagy (Behrends, et al., 2010) exclusively with 
SREBP-1c.  Interestingly, a recent study comparing the three mammalian 
SREBPs in a genome-wide ChIP-seq experiment found that SREBP-2 binds 
preferentially to two different gene-proximal motifs (Seo, et al., 2011).  A Gene 
Ontology (GO) analysis was performed which suggested SREBP-2 targets lipid 
metabolic processes as expected, but apoptosis and autophagy gene categories 
were also enriched (Seo, et al., 2011).  This is a future direction that could 
regulator HEXIM1, and the transcription ac
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po anscription regulation with 
autophagy. 
 Another worthy future direction is the association of ECM29 (KIAA0368) 
with SREBP-2.  ECM29 has been shown to be an adapter protein that interacts 
with molecular motor, endosome components and the 26 S Proteosome (Gorbea, 
et al., 2010).  This is interesting considering the fact that molecular motor 
components, a variety of endosomal components, and many Proteasome 
components are identified in the mass spectrometry datasets.  Other examples of 
putative protein-protein interaction involving ubiquitin signaling and the 
tentially associate the Mediator complex and tr
Proteasome are also found in the data.  There is precedence for ubiquination of a 
transcription factors to rapidly turnover the factor after activation to prevent 
further activation (Salghetti, et al., 2001).  The estrogen receptor also requires 
the 26 S Proteasome for transcriptional activation and subsequent degration of 
the receptor (Lonard, et al., 2000). 
 Finally, a cofactor dramatically enriched in the p53-Mediator complex is 
Rif1, known to regulate the length of telomeres in yeast.  Studies of the human 
Rif1 ortholog suggest a distinct function in double strand DNA damage with the 
kinase ATM (Silverman, et al., 2004; Wang, et al., 2009) which is known to target 
p53.  This is also a very interesting potential future direction for this dataset. 
 
4.4 Methods 
 
 
4.4.1 Activator-Mediator Purifications 
 
 SREBP-1c, SREBP-2, and p65/Rel A were a gift from Anders Näär.  
REBP-1a(1-50), -1c(1-26), -2(1-49), p53(1-70), and p65/RelA(434-551)-
d from HeLa nuclear extract using GST-SREBP-1a (residues 
–50), GST-SREBP-1c (residues 1–26), GST-SREBP-2 (residues 1–49), GST-
, 
ith 
ed 
nt 
, 
S
Mediator was purifie
1
p53 (residues 1–70) and GST-p65/Rel A (residues 434–551) immobilized to 
Glutathione-Sepharose beads (GE Life Sciences).  After binding, the resin was 
washed five times with 10 column volumes (CV) 0.5 M KCl HEGN (20 mM Hepes
pH 7.6; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40 alternative) and one time w
10 CV 0.15 M KCl HEGN (0.02% NP-40 alternative).  Bound proteins were elut
with 30 mM GSH in elution buffer (80 mM Tris, 0.1 mM EDTA, 10% Glycerol, 
0.02% NP-40, 100 mM KCl)and applied to a 15% to 40% linear glycerol gradie
(in 0.15 M KCl HEG) and centrifuged for 6 h at 55,000 rpm.  Mediator-containing 
fractions (>1.0 MDa) were combined for analysis. 
 
4.4.2 Sample Preparation and Proteomics Analysis 
 
 Purified Mediator complex-containing (~1~10ug) fractions were 
precipitated at 4ºC using 20%(w/v) TCA, 0.067mg/mL insulin and 0.067%(w/v) 
deoxycholate.  Precipitated protein pellets were washed twice with -20ºC 
Acetone and air dried.  Proteins were trypsin digested using a slightly modified 
Filter-Aided Sample Prep (FASP) protocol (Wiśniewski, et al., 2009).  Briefly
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protein pellets were suspended with 4%(v/v) SDS, 0.1M Tris pH 8.5, 10mM 
TCEP and incubated 30m ambient to reduce disulfides.  Reduced proteins were 
 
 Tris 
ated 
 
ptides for a second dimension analysis on a 
t 
o 
All spectra were searched with Mascot v2.2 (Matrix Sciences) against the 
 Index (IPI) database version 3.65 with two missed 
leavages and mass tolerances of m/z ±2.0 Da for parent masses and ±0.8 Da 
r MS/MS fragment masses.  Peptides were accepted above a Mascot ion score 
diluted with 8M Urea, 0.1M Tris pH8.5 and iodoacetamide was added to 10mM 
and incubated 30m in total darkness.  Reduced and alkylated proteins were then
transferred to a Microcon YM-30 spin concentrator and washed twice with 8M 
Urea, 0.1M Tris pH 8.5 to remove SDS.  Three washes with 2M Urea, 0.1M
pH8.5 were performed then trypsin and 2mM CaCl2 were added and incub
approximately 2 hours in a 37ºC water bath.  Digested peptides were eluted and 
acidified with 5%(v/v) formic acid.  Peptides were desalted online and 
fractionated with a Phenomenex Jupiter C18 (5µm 300Å; 0.25 x 150mm) column 
using a two dimensional LC/MS/MS method (Agilent 1100).  Seven steps of
increasing acetonitrile (3, 6, 9, 12, 16, 20 and 100%B; A: 20mM ammonium 
formate pH10, 4% acetonitrile and B: 10mM ammonium formate pH10, 65% 
acetonitrile) at 5µL/minute eluted pe
Dionex Acclaim PepMap C18 (3µm 100Å; 0.075 x 150mm) running a gradient a
0.2µL/minute from 5 to 25% B in 100 minutes for steps one through six and 10 t
30% B in 100 minutes for step seven (A: 4% acetonitrile & B: 80% acetonitrile, 
both with 0.1% formic acid pH~2.5).  PepMap eluted peptides were detected with 
an Agilent MSD Trap XCT (3D ion trap) mass spectrometer. 
 
International Protein
c
fo
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corres DR) determined by a separate 
earch of a reversed IPI v3.65 database.  Peptides were then filtered and protein 
-
ponding to a 1% false discovery rate (1% F
s
identifications were assembled using in-house software as described (Meyer
Arendt, et al., 2011; Resing, et al., 2004).
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________________________________________________________________ 
Chapter 5 
Future Directions 
RNA Polymerase II Activity is regulated by post-translational modifications 
 
 
 
 
on the rpb1 C-Terminal Domain 
________________________________________________________________ 
 
5.1 Introduction 
 
 The DNA-dependent RNA Polymerase II (Pol II) is tasked with gene 
expression of all protein-coding genes as well as some non-coding genes.  Pol II 
is made up of 12 subunits with the largest, rpb1 at 220kD and the smallest at 7kD.  
It is unique among DNA-dependent polymerases in that the carboxyl-terminal 
domain (CTD) of rpb1 consists of approximately 40kD of the repeating 
consensus sequence YSPTSPS.  Not all repeats are consensus, however, with a 
two arginines and seven lysines replacing serine at the consensus position 7 in 
the last 20kD of the C-terminus.  This carboxyl-terminal sequence of rpb1 will be 
referred to as the CTD.  The CTD appears to be a target of signaling events 
where phosphorylation of the repeating YSPTSPS correlates with transcription 
initiation and elongation.  The CTD is a large domain for protein-protein 
interactions and it has been shown to bind the Mediator complex (Naar, et al., 
2002), the Integrator complex (Baillat, et al., 2005), mRNA capping, splicing and 
termination cofactors regulating the overall processing of a nascent mRNA 
(Perales and Bentley, 2009).  Many of these cofactors may bind a 
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phosphorylation-pattern-specific state of the CTD.  Antibodies have been used to
show the presence of phosphorylation but very little is known regarding how 
many sites on the CTD are phosphorylated, or whether there is any pattern of 
phosphorylation on the CTD.  Antibodies t
 
o any phosphorylation state of the CTD 
do not convey this information.  Many kinases have been shown to 
phosphorylate the CTD.  The two main kinases relevant to the transcription cycle 
are CDK7 and CDK9.  CDK7 is a component of the general transcription factor II 
H (TFIIH) complex, and CDK9 is part of the positive transcription elongation 
factor b (P-TEFb).  Both of these kinases are purified and used in in vitro kinase 
reactions to phosphorylate a purified GST-fusion of the ~40kD 52-repeat rpb1 
CTD.  This phosphorylated CTD (pCTD) is a very useful reagent for identifying 
new protein-protein interactions specific to the pCTD, as well as for the 
development of a methodology to identify any site-specific pattern of 
phosphorylation on the CTD. 
 
 5.1.1 The Transcription Cycle 
 
 Many protein-protein interactions must be highly coordinated in a spatial 
and temporal fashion during the transcription cycle.  The minimum composition of 
factors required appears to be the general transcription machinery:  TFIIA, TFIIB, 
TFIID, TFIIE, TFIIF, TFIIH, The Mediator complex and RNA Pol II (Taatjes, 2010).  
This is often referred to as the pre-initiation complex (PIC).  Transcription 
initiation is followed by elongation, though the rate can vary widely depending on 
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the promoter and stimulation.  This transition is becoming a new focus for 
transcription regulation.  The CTD is phosphorylated during this transcription 
cycle at the promoter of genes by TFIIH which is also tasked with promoter 
melting in preparation for elongation.  TFIIH phosphorylates serine five and 
seven of the consensus  is thought Pol II is 
longation complex (PEC) (Taatjes, 2010).  Additional phosphorylation events 
then occur where P-TEFb phosphorylates the CTD on serine two of the repeats 
YSPTSPS as well as other elongation factors, such as NELF and DSIF (SPT4 
and SPT5) allowing for productive elongation.  It is thought that the pCTD 
electrostatically repels Mediator and the PEC to assist in departure from the 
promoter (Sogaard and Svejstrup, 2007 and Kim, et al., 1994).  The CTD is often 
thought of as a large binding platform, where phosphorylation can dramatically 
change the sequence landscape regulating protein-protein interactions.  Of 
course what goes on must come off, so there are phosphatases that must 
remove the phosphate groups to ‘reset’ the Pol II for additional transcription 
events and the cycle can then start over. 
 
 5.1.2 Cotranscriptional mRNA Processing and the CTD code 
 
 Concurrent with the transcription cycle is the processing of the nascent 
RNA as well as passage through chromatin.  Many cofactors and protein 
complexes have been demonstrated to be involved.  The mature mRNA must be 
 repeats YSPTSPS.  At this point it
ready for elongation, so this protein assembly is really more accurately a pre-
e
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capped, spliced together and polyadenylated/terminated then prepared for export 
out of the nucleus.  At the same time, chromatin must be cleared by chromati
remodeling factors.  The CTD provides a flexible and reasonably large binding 
platform to coordinate assembly of chromatin remodeling complexes, the 
spliceosome, and the Integrator complex, which has been shown to 
small nuclear RNA (snRNA).  The exact CTD or pCTD substrates for these 
protein-protein interactions are unknown. 
 Here we undertake an experiment to comprehensively characterize the
HeLa nuclear extract interactome of the CTD in distinct phosphorylation states: 
(1) unphosphorylated, (2) phosphorylated serine five only (TFIIH only), (3) 
phosphorylated serine two only (P-TEFb only), and (4) phosphorylated serine fiv
and two (TFIIH and P-TEFb both).  We identify known CTD-interacting p
complexes:  the Integrator and the Mediator complexes.  Many other p
cofactors and likely complexes
n 
process 
 
e 
rotein 
rotein 
 are also identified. 
To address the question of a phosphorylation pattern on the CTD, very 
uence and lack of protease 
leavage sites make traditional mass spectrometry incapable of sequencing 
 
preliminary data will be presented.  The repeating seq
c
more than half of the CTD.  This strategy is based on chemical biology, “middle-
down” proteomics using a supercharging reagent to enhance ionization and 
charge density along with all available gas phase fragmentation and fractionation 
methods. 
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5.2 Results 
 
 A proteomics platform was applied to characterize phosphorylation-
specific CTD-interacting cofactors.  Approximately 35~50 ug GST-CTD was 
phosphorylated by (1) TFIIH, (2) P-TEFb, and (3) TFIIH and P-TEFb both. 
 It was expected that Mediator would only interact with the 
unphosphorylated CTD or at least there would be much less depending on the 
actual amount of phosphorylation on any given CTD molecule.  This, however, 
was not the case.  If fact, there appears to be as much or more Mediator in any
of the pCTD as the unphosphorylated control CTD sample, suggesting that
perhaps phosphorylation alone is not the dissociating action for Mediator and
CTD. 
 Another interesting result was identification of the Integrator complex in 
both the CTD and pCTD samples.  It was reported that serine seven must be
phosphorylated for recruitment of Integrator (Egloff, et al., 2007), but Integr
was identified in all pCTD regardless of kinase.  So this leaves the questions
what regulates the recruitment of either M
 
 
 the 
 
ator 
 to 
ediator or Integrator, or is both able to 
teract simultaneously? 
5.2.1 CTD Substrate and Kinases 
 
in
 
 
 
 To obtain a sufficient amount of phosphorylated CTD to perform 
experiments, an expressed fusion protein GST-rpb1-CTD is purified (Figure 5.1).  
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 Figure 5.1  Purification of GST-rpb1-CTD.  (A) The fusion protein GST-rpb1-CTD used in 
 (C) Coomassie stain acrylamide this study.  (B) Purification scheme for GST-rpb1-CTD. 
gel of Superdex 200 fractions. 
Figure 5.2  Purification of TFIIH.  (A) 
 Purification scheme.  (B) Silver stain
acrylamide gel. 
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A two-step purification is employed from BL21 lysates, with a GSH-Sepharose 
olumn followed by a Superdex 200 gel filtration column.  The gel filtration 
 
Figure 5.3  Purification of P
acrylamide of elution from Ni-NT
-TEFb.  (A) Purification scheme.  (B) Coomassie stained 
A purification and westerns for cyclin T1 and CDK9.  
(C) Mono S fractions of P-TEFb. 
c
column effectively removes the excess truncated fusion proteins that are
characteristic of GST-CTD expressions.  The early gel filtration fractions contain 
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very pure GST-CTD for in vitro kinase reactions which can then be immobilized 
again. 
 The two major CTD kinases were also purified.  TFIIH is purified in the lab 
from P1.0M/Qft/anti-ERCC3 (TFIIH) affinity column (Figure 5.2).  P-TEFb is 
purified from recombinant Sf9 cells co-infected with His6X-CDK9 and Cyclin T1 
(Figure 5.3).  Sf9 lysates were incubated in batch with Ni-NTA agarose, washed 
and eluted with imidazole (Figure 5.3. A and B).  The imidazole elution was then 
loaded onto a MonoS for a gradient elution (Figure 5.3.C).  P-TEFb-containing 
fractions were used in kinase reactions with GST-CTD. 
 
 5.2.2 The RNA Pol II CTD and Phospho-CTD Interactomes 
 
 Kinase reactions were performed with 35~50 ug purified GST-CTD, TFIIH 
112 
a  
TFIIH and P-TEFb.  The amount of phosphorylation can clearly be seen in this 
D runs at approximately 85kD.  As the 
e
slower migrating bands with a finite band where apparently no more 
phosphorylation takes place at approximately 125kD.  So neither the purified 
TFIIH nor the P-TEFb can completely phosphorylate this substrate GST-CTD in 
solution with purified components only.  These kinase reaction were performed at 
the same scale in 18X replicates for each TFIIH only, P-TEFb only, and TFIIH 
and P-TEFb both, along with an unphosphorylated CTD control (Figure 5.5). 
nd P-TEFb.  Figure 5.4 shows a typical timecourse to an hour at 37ºC with both
silver stained acrylamide gel.  The GST-CT
CTD become more and more phosphorylat d the band smears to slower and 
Figure 5.4  Kinase reaction timecourse with GST-CTD and TFIIH or P-TEFb.  Silver stained 
acrylamide gel of T0, T15m, T30m and T60m timecourse. 
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Figure 5.5  Immobilization of kinase reactions with GSH-Sepharose and beads af
Sarkosyl elution to verify fusion protein phosphorylation throughout the nuclear
ter 
 extract 
pulldowns. 
The kinase reactions were passed over a GSH-Sepharose column (Figure 5.6.A
The input and flow through of each kinase reaction is shown in Figure 5.5.  The 
immobilized GST-CTD and GST-pCTD were washed with 0.15M KCl buffer to 
remove the kinase reaction components.  The buffer was removed an
HeLa nuclear extract supplemented with phosphatase inhibitors was added an
mixed at 4ºC for 3 hours.  The pulldowns were washed with 0.5M KCl buffer and 
eluted with 2% (w/v) sarkosyl for mass spectrometry anlaysis.  The remaining 
beads, with most of the fusion protein still immobilized, were then eluted with 
Laemli sample loading buffer (Figure 5.5 “BEADS”) to show that the amount o
).  
d cleared 
d 
f 
phosphorylation had not significantly changed throughout the pulldown. 
Figure 5.6  Purification of phosphorylated CTD-binding proteins.  (A) Purification 
schem
phosp
e.  (B) Silver stained acrylamide gel of CTD-interacting proteins and 
horylatetd CTD-interacting proteins. 
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 ed by 
ed in this analysis is 
 
 number of peptides identified 
for the Mediator (Tables 5.1 and 5.2) and Integrator (Tables 5.1 and 5.3) 
 
complexes in the pCTD samples. 
If phosphorylation of the CTD disrupts the interaction with Mediator, then 
why is there so much Mediator in all of the pCTD samples?  Certainly, not all of 
the available sites are phosphorylated and it may only require two to four repeats 
unphosphorylated CTD.  What is unexpected is the
The sarkosyl elutions (Figure 5.6.B) were prepared for and analyz
mass spectrometry.  The total number of proteins identifi
given in Table 5.1, along with the totals for two major complexes that are known 
to bind the CTD, Mediator and Integrator. 
Every effort was made match the CTD and pCTD pulldown samples in 
terms of amount of bait and nuclear extract input.  And yet more proteins were 
indentfied in each of the pCTD compared to the CTD control.  In fact, as much as 
a third more total proteins were identified in the TFIIH pCTD sample as the CTD 
control (Table 5.1).  This is not unexpected if phosphorylation of the CTD is 
meant to induce the recruitment of cofactors that do not bind the 
Table 5.1  Total identifications for CTD/pCTD-interactome. 
TFIIH P-TEFb TFIIH+P-TEF
CTD control pCTD pCTD pCTD
total peptides 4073 8013 5628 6346
total proteins 366 757 612 660
b
total MEDIATOR peptides 214 365 305 300
ator peptides 532 1042 1109 1175
total Integrator proteins 12 12 12 12
total MEDIATOR proteins 20 26 24 25
total Integr
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Control PTEFb TFIIHpCTD TFIIH+PTEFb
CTD pCTD pCTD pCTD Gene Prot MW
41 70 56 54 MED1 168478
6 7 17 15 MED4 29745
0 0 1 0 MED6 29298
11 8 8 4 MED7 27245
9 12 10 8 MED8 32819
0 10 0 0 MED9 16403
4 1 2 5 MED10 15688
0 1 4 4 MED11 13129
0 0 0 1 MED12 247334
31 26 42 26 MED14 160607
12 31 37 23 MED15 86753
15 12 12 20 MED16 96793
7 24 35 23 MED17 72876
0 0 0 1 MED18 24453
1 4 5 4 MED19 26273
9 10 20 6 MED20 23222
7 9 9 9 MED21 15564
to bind the Mediator, however, less Mediator would still be expected if the pCTD
did not bind Mediator. 
 Another unexpected result was the amount Integrator complex in the CTD 
sample as well as all pCTD samples.  There appears to be an enrichment of 
Integrator in the pCTD compare with the CTD control (Table 5.3), however, the
are still more than twice the spectral counts for Integrator than the comparably 
 
re 
0 2 7 10 MED22 16480
0305
0 MED25 84389
7 20 9 12 MED26 65446
4 5 5 18 MED23 156194
21 24 27 30 MED24 11
0 1 16
18 9 20 7 MED27 35432
0 0 3 2 MED28 19520
1 12 6 9 MED29 23473
4 7 11 9 MED30 20277
6 0 3 0 MED31 15805
Table 5.2  Mediator identifications for CTD/pCTD. 
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sized Mediator complex in the CTD control.  So phosphorylation d
to be required for the GST-CTD to bind the Integrator complex in nuclear extract. 
 An interesting internal control was found with the factor Phosphory
CTD-Interacting Factor 1 (PCIF1). 
oes not appear 
lated 
 PCIF1 was identified as a pCTD-interacting 
 
y 
factor that did not bind the unphosphorylated CTD (Fan, et al. 2003) and the data
presented here (Table 5.4) confirms this.  The spectral counts for PCIF1 are fairl
well matched for each pCTD sample. 
TFIIH+
Control PTEFb TFIIH PTEFb
CTD pCTD pCTD pCTD Gene Prot MW Protein descriptor
0 20 23 26 PCIF1 81351  PHOSPHORYLATED CTD-INTERACTING FACTOR1
 To further validate the Mediator association with the pCTD, the samples 
prepared for mass spectrometry were probed by western blotting for MED1 and 
MED23 (Figure 5.7).  And in fact, the western blot did confirm the mass 
Control PTEFb TFIIHpCTD TFIIH+PTEFb
CTD pCTD pCTD pCTD Gene Prot MW
47 95 73
95 195 235 202 INTS1 244297
105 INTS2 134346
51 152 165 228 INTS3 118013
6
22 53 41 52 INTS5 107995
93 123 132 146 INTS7 106834
28 48 33 42 INTS9 73814
11 53 27 42 CPSF3L 67663
0 151 120 119 INTS4 108171
107 150 114 175 INTS6 100390
33 67 58 44 INTS8 113088
4 45 48 43 INTS10 82236
10 13 22 28 INTS12 48808
Table 5.3  Integrator identifications for CTD/pCTD. 
Table 5.4  PCIF1 is an Internal control identified only in 
phosphorylated CTD pulldowns. 
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spectrometry data with more MED1 and MED23 in the pCTD samples relative to 
the CTD control. 
 To test whether the pCTD-Mediator interaction was through accessory 
cofactors and not direct as it was with the unphosphorylated CTD, the input for 
Figure 5.7  Western blot probing MED1 and MED23 in CTD/pCTD elutions. 
purifying Mediator was put over two chromatography columns, a 
phosphocellulose P11 followed by a Poros Q column for an enriched Mediator 
fraction (Figure 5.8.A).  The bait was unphosphorylated CTD and CTD 
phosphorylated by both TFIIH and P-TEFb.  Mediator was bound to both CTD 
and pCTD from the P1.0M/Q1.0M fraction (Figure 5.8.B).  These CTD/pCTD 
purified Mediator fractions were applied to a Superose 6 gel filtration column to 
isolate the CTD/pCTD-bound Mediator complexes.  However, no Mediator eluted 
from the Superose 6 column in any experiment.  Two possible explanations for 
118 
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this phenomena are (1) the Mediator complex broke up inside the column 
(though no subunits were identified in 
Figure 5.8  CTD/pCTD pulldowns from Mediator-enriched fraction, P1.0M/Q1.0M.  (A) 
Purification scheme.  (B) Silver stained acrylamide of CTD/pCTD elutions. 
their molecular weight range), or (2) the 
M centrations used 
(0
 
5.2.3 A Strategy for the Identification of Site-Specific 
ediator complex bound indefinitely to the resin at the salt con
.15M KCl). 
Phosphorylation on the RNA Pol II CTD 
 
 A traditional “bottom-up” experiment, such as those offered in Chapters 2, 
3 and 4, uses the protease trypsin to reduce target proteins into peptides that can 
be sequenced by a mass spectrometer.  The problem with the CTD is that only 
half of it has any trypsin-substrate lysines or arginines, the distal half, and the 
inases required for phosphorylating the CTD are difficult 
 
 
 involves: 
other half, the proximal half, is over 21kD.  This is far too large for traditional 
collision-induced dissociation (CID) gas-phase fragmentation.  It is possible, 
however, with a high resolution mass spectrometer that a 21kD polypeptide could 
be analyzed in a “middle-down” experiment (Siuti and Kelleher, 2007).  Another 
problem, however, is that a 21kD polypeptide with few basic residues can be a 
challenge to ionize and get into the gas phase.  These are difficult analytical 
problems that likely have hindered the successful sequencing of the repeating 
heptad sequence of the CTD using mass spectrometry.  Further complicating the 
issue is that the k
reagents to obtain.  Unfortunately, purifying kinases and the GST fusion protein
and performing kinase reactions to generate phosphorylated CTD is the easiest
part of characterizing a pattern of phosphorylation on the CTD. 
 A strategy for sequencing the repeats of the CTD to identify site-specific 
modifications and preliminary data will be presented here.  The strategy
 1.  Peptide mapping and hplc purification; 
 2.  Chemical biology (beta-Elimination/Michael Addition); 
 3.  Supercharging reagent to enhance ionization; 
 4.  All available gas-phase fragmentation (ETD, HCD, CID); 
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All aspects of this strategy work together to provide a solid methodology to tackle 
this intensive analytical problem that is of great relevance to understanding 
molecular mechanisms of gene activation.  The hplc purification and peptide 
mapping of CTD polypeptides simplify the downstream analyses and allow for 
greater flexibility in analyses.  A supercharging reagent (Iavarone, et al., 2001) 
has been tested with great success in increasing the charge states observed for 
the 21kD polypeptide, though fragmentation efficiency did not benefit as greatly.  
New technology is available to fragment polypeptides in the gas phase, such as 
electron transfer dissociation (ETD) and higher-energy collision dissociation 
(HCD) which may provide high sequencing coverage.  However, ETD works 
better with a higher charge density (Syka, et al., 2004).  Phosphorylation adds 
negative charge neutralizing the positive charge on the CTD.  If the negatively 
ch n 
the charge density would be increased, likely improving the ETD sequencing 
The 
 a lysine analog that can be proteolyzed by trypsin or Lys-C 
igure 5.9) (Knight, et al., 2003; Rusnak, et al., 2004).  Trypsin would only 
arged phosphorylation could be converted to a positively charged group, the
efficiency.  This chemistry is called beta-elimination and Michael Addition.  
phosphate is removed by barium catalyzed beta-elimination leaving a 
dehydroalanine which can be reacted with the nucleophile amino-ethyl thiol 
(AET) to leave
(F
Figure 5.9  (Knight, et al., 2003) Beta-elimination and Michael addition of amino-ethyl 
thiol (AET) converts phospho-serine to lysine analog that is cleavable using Lys-C 
endoproteinase. 
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cleave the position seven with greater efficiency since positions two and five are 
followed by prolines, which block trypsin access to the active site.  Lys-C can be 
used to cleave through adjacent prolines where a phopho-serine would allow for
peptide mapping revealing the position of phosphorylation again with peptide 
mapping. 
 Peptide mapping experiments were performed with trypsin, Lys-C and 
Arg-C.  Trypsin gives the most number of CTD peptides, Lys-C gives one fewer 
and Arg-C gives just two, a promixal and distal CTD polypeptide.  The GST-CTD
(pGEX-4T3) fusion protein has a thrombin cleavage site, so the kinase reactions
are performed in solution, then the reactions were precipitated with 1% formic 
acid and 80%(v/v) Acetone to remove reaction components.  The pellets were 
suspended with 8M urea, diluted to 2M and thrombin digested for 15 minutes at 
ambient then loaded onto a reversed-phase C18 hplc column where the ~4
CTD was collected.  The CTD polypeptide was lyophilized then suspended in 
0.1M Tris pH 8.5 for trypsin digestion.  The tryptic peptides were again loaded 
onto a reversed-phase C18 hplc column (Figure 5.10).  Each CT
 
 
 
0kD 
D peak was 
es that sequence as a 
 repeats) were 
at are a single repeat 
 asterisks are 
peptides that belong to trypsin.  The next experiment was to perform kinase  
manually collected and analyzed using MALDI-TOF-MS to give parent masses 
for each peptide (Figure 5.10).  The first CTD repeat was lost during the thrombin 
cleavage and CTD, as it appears thrombin also us
substrate.  However, all other expected CTD peptides (~49 of 52
identified in this fashion.  There are two tryptic peptides th
that are too hydrophilic and do not retain on the rpC18 column.  The
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Figure 5.10  Peptide mapping the CTD.  Reversed-phase C18 UV 215nm trace of tryptic 
CTD peptides.  Single repeats (two in the CTD) are not retained. (* are peptides of 
trypsin) 
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Figure 5.11  Peptide mapping the pCTD.  Reversed-phase C18 UV 215nm trace of tryptic 
CTD and pCTD peptides.  Addition of TFIIH kinase prior to trypsin digestion (red) and 
twice the TFIIH  (green).  Single repeats (two in the CTD) are not retained. (* are 
peptides of trypsin) 
reactions with the GST-CTD and TFIIH, such as in Figure 5.4.  Two titrations (1X 
and 2X) of TFIIH kinase were added to GST-CTD and incubated at 37ºC for 
maximum kinase activity.  The experiment was repeated with Thrombin digestion 
of the fusion protein, C18 purification of the ~40kD pCTD and trypsin digestion
followed by
 
 another C18 column (Figure 5.11).  Again, all peaks were collected 
ed 
or 
ight, 
h 
TSPS) 
-
re 
and analyzed using MALDI-TOF-MS for parent masses and peptide mapping.  
There are only small peaks that rise up in the kinase reaction samples which 
have masses consistent with phosphorylated CTD peptides, but there is no 
complete conversion from unphosphorylated to completely phosphorylated in 
these TFIIH experiments. 
 The phosphorylated CTD peptides collected in Figure 5.11 were then us
for subsequent experiments to develop a beta-elimination/Michael addition 
protocol (Figure 5.9).  There is a fairly large body of literature dealing with beta-
elimination of phosphorylated serine and threonine residues, however, two 
groups (Shokat and Hathaway) have applied this chemistry with a nucleophile f
the Michael Addition that is compatible with trypsin and Lys-C active sites (Kn
et al., 2003; Rusnak, et al., 2002 & 2004).  Development experiments began wit
conditions offered as optimal for the model proteins used in these studies.  In the 
methods of Knight, et al., 2003, pTP and pSP sequences (the CTD is YSP
required 2h at 37ºC as opposed to 1h at ambient for all other peptides.  The beta
elimination occurs at high pH, which can hydrolyze peptides.  Therefore, 
conditions must be established that optimize beta-elimination/Michael Addition 
reaction completion and minimize peptide degradation.  Critical parameters a
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temperature, time, solvent, basicity and the order of addition.  These are many 
parameters to vary with very little pCTD substrate.  Therefore, conditions were 
tested as published (Knight, et al., 2003) with limited success.  Several 
experiments were performed with no products at all.  Upon further investigation in 
the literature, intramolecular linkage are common in beta-elimination reactions 
and that the hydrophobicity of the solvent can be a critical parameter for pTP and 
pSP sequences (Tinette, et al., 2007).  Therefore, the hydrophobicity of the 
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reactions was increased with the addition 
products had been identified, a much shor
peaks were discovered at 5m that were gone at 10m, so other reactions were 
c
 
 
ontaining sequence of the CTD. 
clearly taking place leaving no desired products.  Finally, an experiment testing 
5m beta-elimination and 10m sequential Michael Addition provided a product 
peak with a mass consistent with a modified CTD peptide (Figure 5.12).  This 
experiment was run on an LC/MS instead of the UV-hplc, which allowed for 
partial MS/MS sequencing.  The sequencing data is also consistent with the 
correct Michael Addition product for the two repeat pCTD peptide used for this 
experiment (Figure 5.13).  This reaction did not go to completion, however, it was 
the first experiment to successfully provide the correct product or any product for 
that matter.  Further development experiments will be required to optimize the 
beta-elimination/Michael addition for the unique repeating, serine/proline-
of 50% (v/v) acetonitrile, and since no 
ter timepoint was tested.  Product 
 Figure 5.12  LC/MS total ion count (TIC) chromatograms of Beta-elimination/Michael 
to be a formylation product not resolved on the first column (Figure 5.10). 
addition of 2X CTD repeats with a single phophorylation.  The 810m/z peak is thought 
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 Figure 5.13  Beta-elimination/Michae
phophorylation.  The 810m/z peak is 
l addition of 2X CTD repeats with a single 
thought to be a formylation product since it does 
not match any expected masses. 
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cha
spe  
interpretable results.  A new quadrapole-time of flight (Q-TOF) mass 
spectrometer with ETD, HCD and CID will allow the interrogation of spectra up to 
rge states are shown, which greatly increases the complexity of the mass 
ctrum.  A different style of mass analyzer may provide more readily
The advantage of purifying kinase reaction products is the variety of actual 
CTD substrate peptides, as opposed to ordering a synthetic pCTD peptide, which 
would be much more expensive and may not be representative of all pCTD 
peptides.  Future development experiments will employ the CTD kinase P-TEFb 
which is recombinantly expressed in bacalovirus and exhibits somewhat greater 
activity with the CTD than the endogenous purifications of TFIIH.  More 
phosphorylated CTD products will allow for more thorough development 
experiment to optimize the beta-elimination/Michael Addition chemistry.  
Successful application of this chemistry with the ~21kD pCTD fragment would 
convert negatively charged phosphates to positively charged lysine analogs, 
increasing the charge density improving ionization, along with a supercharging 
reagent, also improving sequencing efficiency with gas-phase ETD fragmentation 
(Syka, et al., 2004).  ETD has been tested (without the beta-elimination/Michael 
Addition chemistry) with an Orbitrap Velos using a supercharging reagent.  Only 
a small portion of the ~21kD CTD fragment was fragmented, but theoretical c-
ions were identified, so it can be done.  Increasing sequencing efficiency will be 
required for a successful method to characterize a pattern of modification on the 
CTD.  Although, for the Orbitrap, which has a fairly narrow mass window 
compared with other types of mass analyzers (only up to ~3kD), only multiple 
100kD.  The full option of gas-phase fragmentation and the “top-down/middle-
down” capability of the Q-TOF may provide the data to identify site-specific 
modification of a highly purified pCTD. 
 
5.3 Discussion 
 
 RNA Pol II is the protein really at the center of it all in terms of gene 
activation.  The responsibility of this protein is great in terms of being highly 
regulated for activation, but once activated, it must negotiate through a chromatin 
environment for productive transcription and elongation, and then it must ensure 
the processing of nascent mRNA transcripts.  This involves coordinating the 
timely arrival of mRNA Capping enzymes at the initiation of transcription and then 
coordinating the Spliceosome to remove intronic sequences, and finally cofactors 
that polyadenylated and terminate the 3’-end of the mRNA transcript.  The ~40kD 
CTD is the business portion for these critical protein-protein interactions.  
Phosphorylation of the CTD appears to be a molecular mechanism for regulating 
the spatial and temporal protein-protein interactions crucial for transcription-
coupled mRNA processing.  The modification of such a large repeating sequence 
begs the question of a “CTD Code” or a pattern of modification that is specific for 
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distinct binding domains.  This would allow for substrate specificity and affinity to 
b
experiments could be performed with a method to accurately identify site-specific 
e regulated by associating cofactors, such as the Mediator complex.  These 
phosphorylation or any modification on the CTD.  Furthermore, the benefits of 
these types of experiments are: 
 
 1.  True substrate recognized by RNA Processing Factors 
 2.  Define unique biologically relevant epitopes for production of antibodies
 3.  Biochemical purification of factors interacting with Phospho-CT
 4.  Establish CTD phospho-patterns: mRNA processing and transc
 5.  Mechanistic insight into CTD kinase specificity and processivity
 
 To our knowledge the entire ~40kD CTD has never been used to probe
the protein-protein interactions, or the CTD interactome, in a cell.  Small synthet
peptides have been used, but never the actual endogenous substrate that is the 
full length CTD.  It is somewhat challenging to express and purify even the GST-
CTD fusion protein to do experiment such as this, let alone the kinases that 
modify it.  Having derived highly purified reagents for these experiments, the 
CTD was phosphorylated and used to pulldown HeLa nuclear extract.  Both of 
the known major kinases were used to phosphorylate the CTD and a 
combination of both with the addition of a non-phophorylated control CTD
These four samples were analyzed by mass spectrometry to characterize the 
nuclear interactome of each ‘phosphorylation state’ of the GST-CTD fusion.  
Every effort was made to match the GST-CTD pulldowns.  The most stri
results are the interactions of the Integrator and Mediator complexes 
both the unphosphorylated and phosphorylated CTD.  It has been thought for 
 
D motifs 
ription 
. 
 
ic 
.  
king 
with the 
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many years that the phosphorylation of the CTD is what dissociations the PIC,
Mediator and RNA Pol II, via electrostatic repulsion of the negatively charge
phosphate groups.  Not all of the CTD r
 
d 
epeats are phosphorylated in any of the 
amples used for pulldowns, however, it would be expected that there would be 
TD pulldowns.  Western blotting has confirmed the 
ssociation of Mediator with a phosphorylated CTD.  To test whether additional 
 not a 
 
q) 
ing Pol 
 
s
less Mediator in the pC
a
cofactors were likely linking the Mediator complex to the pCTD and that it is
direct interaction, a column fraction enriched in Mediator (P1.0M/Q1.0M) was
used for an input of both the unphosphorylated and a TFIIH/P-TEFb 
phosphorylated CTD.  Mediator was pulled-down by both the CTD and pCTD.  
This data fits nicely with chromatin immunoprecipitation-sequencing (ChIP-Se
data showing Mediator colocalizing with serine 5 phosphorylated RNA Pol II 
(Kagey, et al., 2010; Takahashi, et al., 2011).  A future direction for these 
experiments is to repeat them with purified endogenous RNA Pol II complex.  If 
Mediator binds the phosphorylated CTD, then that is not the cue for releas
II from the promoter, and there is some other mechanism coinciding with 
phosphorylation of the CTD. 
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5.4 Methods 
 
5.4.1 GST-CTD Purification 
TG 
en added to 0.5 mM and the induction was overnight at 13ºC.  Cell pellets were 
 
 
t al., 
 
 The 52-repeat CTD of rpb1 (residues 1593-1970) was cloned into a 
pGEX-4T-3 vector for bacterial expression.  The fusion protein was transformed 
into Codon Plus RIPL BL21 strain (Stratagene) which contains rare codons in 
bacteria.  The BL21s were grown at 37ºC to OD 0.6 iced for 10 minutes.  IP
th
lysed and purified using a standard GSH-Sepharose purification.  The GST-CTD
fusion protein was eluted with 30 mM GSH and concentrated with a Microcon 
spin filter.  The concentrated GST-CTD was loaded onto a Superdex 200 gel 
filtration column and 0.3 mL fractions were collected and analyzed by acrylamide
gel and coomassie staining.  Fractions were stored at -80ºC. 
 
5.4.2 Purification of CTD Kinases 
 
 TFIIH was purified from HeLa nuclear extract as reported (Kneusel, e
2009) and P-TEFb was purified from Sf9 bacalovirus cell pellets as reported 
(Tahirov, et al., 2010). 
 
5.4.3 Purification of Phospho-CTD Interacting cofactors 
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 To generate the phosphorylated CTD baits for pulldowns, kinase reaction
were performed with purified GST-CTD, TFIIH and P-TEFb as reported (Knues
et al., 2009).  The kinase reactions were added to washed GSH-Sepharose 
beads and incubated 1h at 4ºC.  Two 0.15M HEGN washes removed the kinase 
reactions and all buffer was taken off the beads.  Cleared HeLa nuclear ext
supplemented with Microcystin LR, sodium orthovanadate, sodium fluoride, 
sodium pyrophosphate and beta-glycerophosphate was added to the CTD/pCTD 
immobilized beads.  Pulldowns were incubated 3h at 4ºC.  After binding, the re
was washed five times with 10 column volumes (CV) 0.5 M KCl HEG
Hepes, pH 7.6; 0.1 mM EDTA; 10% Glycerol; 0.1% NP-40 alternative) and one 
time with 10 CV 0.15 M KCl HEGN (0.02% NP-40 alternative).  Bound proteins 
were eluted with 2% (w/v) Sarkosyl in elution buffer (80 mM Tris, 0.1 mM EDT
10% Glycerol, 0.02% NP-40, 100 mM KCl). 
 
5.4.4 Proteomics Analysis of the Phospho-CTD Interactome 
 
 Sarkosyl elutions from
s 
el, 
ract 
sin 
N (20 mM 
A, 
 GST-CTD and GST-pCTD (TFIIH, P-TEFb and 
oth TFIIH & P-TEFb) pulldowns from HeLa NE were precipitated at 4ºC using 
0%(w/v) TCA, 0.067mg/mL insulin and 0.067%(w/v) deoxycholate.  Precipitated 
rotein pellets were washed twice with -20ºC Acetone and air dried.  Proteins 
ere trypsin digested using a slightly modified Filter-Aided Sample Prep (FASP) 
rotocol (Wiśniewski, et al., 2009). Briefly, protein pellets were suspended with 
%(v/v) SDS, 0.1M Tris pH 8.5, 10mM TCEP and incubated 30m ambient to 
b
2
p
w
p
4
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reduce disulfides.  Reduced proteins were diluted with 8M Urea, 0.1M Tris pH8.5 
nd iodoacetamide was added to 10mM and incubated 30m in total darkness. 
Reduc hen transferred to a Microcon YM-30 spin 
oncentrator and washed twice with 8M Urea, 0.1M Tris pH 8.5 to remove SDS. 
as 
 
4, 
henomenex Jupiter Proteo C12 (4µm 90Å; 0.075 x ~300mm) running a gradient 
at 0.2µ es for steps one through six and 10 
 30% B in 100 minutes for step seven (A: 4% acetonitrile & B: 80% acetonitrile, 
searched with Mascot v2.2 (Matrix Sciences) against the 
ternational Protein Index (IPI) database version 3.65 with two missed 
cleava d  ±0.8 Da 
r MS/MS fragment masses. Peptides were accepted above a Mascot ion score 
a
ed and alkylated proteins were t
c
Three washes with 2M Urea, 0.1M Tris pH8.5 were performed then Lys-C w
added and incubated overnight at ambient on a nutator.  Trypsin and 2mM CaCl2
were added and incubated approximately 4 hours in a 37ºC dry incubator on a 
nutator. Digested peptides were eluted and acidified with ~5% (v/v) formic acid. 
 Peptides were desalted online and fractionated with a Phenomenex 
Jupiter C18 (5µm 300Å; 0.25 x 150mm) column using a two dimensional 
LC/MS/MS method (Agilent 1100). Thirteen steps of increasing acetonitrile (2, 
6, 8, 10, 12, 15, 18, 21, 25, 30, 50 and 100%B; A: 20mM ammonium formate 
pH10, 4% acetonitrile and B: 10mM ammonium formate pH10, 65% acetonitrile) 
at 5µL/minute eluted peptides for a second dimension analysis on a 
P
L/minute from 5 to 25% B in 100 minut
to
both with 0.1% formic acid pH~2.5). Eluted peptides were detected with an 
Agilent MSD Trap XCT (3D ion trap) mass spectrometer. 
 All spectra were 
In
ges an  mass tolerances of m/z ±2.0 Da for parent masses and
fo
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corresponding to a 1% false discovery rate (1% FDR) determined by a separate 
search of a reversed IPI v3.65 database. Peptides were then filtered and protein 
identifications were assembled using in-house software as described (Meyer
Arendt, et al., 2011; Resing, et al., 2004).
-
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Appendix 1.  Protein Precipitati
h 0.15M HEGN (for a saturated insulin solution). 
  _____________mg Insulin /~__________mL 0.15M HEGN. 
__-fold. 
 
0µL 1% DOC        X______~_______ µL 
. 
on protocol 
 
□1.  Combined Sample Fractions_____________, Total Volume: __________µL. 
 
□2.  Prepare 1.0mg/mL Insulin wit
 
□3.  Divide Total Sample Volume: _____________µL / 100µL ~________
□4.  For every 100µL sample add in order immediately on ice then vortex: 
    10µL 1.0mg/mL Insulin X______~_______ µL 
     1
     30µL TCA         X______~_______ µL 
 
□5.  Incubate on ice 20m then Centrifuge 14,000rpm, 4C, 30m. 
 
□6.  Aspirate Supernatant & Add 0.5mL Acetone(-20C) wash then vortex. 
 
□7.  Incubate on ice 10m then Centrifuge 14,000rpm, 4C, 15m. 
 
□8.  Repeat steps 6. & 7.:  0.5mL Acetone(-20C) wash, vortex, incubate, 
centrifuge. 
 
□9.  Aspirate Supernatant & Air Dry Pellet. 
 
□10.  Store Dry Pellet at -80C
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Appendix 2. Filter-Aided Sampl (FASP) for mass spectrometry 
5µL) 
□2.  Prepare FRESH 8M Urea, 0.1M Tris pH 8.5 (weigh 0.6~0.7g in 1.5mL tube) 
C water 
□3.  Prepare 2M Urea, 0.1M Tris pH 8.5…  (500µL)  [UB] 
µL 4% SDS… Did it go into 
 ambient to Reduce all proteins… 
… & 
 in 
 
…  
 
 
n 
y mix ~1m… Transfers filter to a Fresh Collection tube & Wrap with 
ntly 
 in 37ºC waterbath for _______… 
 
□12.  Centrifuge 14,000rpm ~15min… Transfer _____µL FT to a 0.5mL low-
retention tube … 
 
□13.  Add 50µL 0.5M NaCl in HPLC Water & Centrifuge 14,000rpm ~15min… 
Combine _____µL FT in 0.5mL low-retention tube … 
 
□14.  Freeze & store -80C... 
 
e Preparation 
 
□1.  Prepare 4% SDS, 0.1M Tris pH 8.5, 10mM TCEP…  (100µL)  [4% SDS] 
  ____________µL 20% SDS(20µL)        __________µL 0.1M TCEP(10µL) 
  ____________µL 2M Tris pH8.5(5µL)   __________µL HPLC water(6
 
  _____________mg Urea/FW60.06*8M ~_____________mL total  [UA] 
  _____________µL 2M Tris pH8.5 _____________µL HPL
 
  _____________µL 2M Tris pH8.5 (25µL) _____________µL UA (125µL) 
  _____________µL HPLC water (350µL) 
 
□4.  Suspend ~________µg protein pellet(s) with 30
solution? If YES, then & Incubate 20~30m
go on to step 5. If NO, then Add 200µL UA and 20µL 0.1M TCEP & 
Incubate 20~30m ambient to Reduce all proteins… 
 
□5.  Add 200µL UA to 30µL SDS suspended pellet… if it hasn’t been already
Add 13µL 0.5M Iodoacetamide for ~25mM… Incubate 20~30m wrapped
foil (dark)… 
 
□6.  Add 200µL UA to YM-30 (Microcon) & centrifuge 14,000rpm ~5min to
wash… Discard FT… Flip the filter & spin out any residual UA
□7.  Add reduced/alkylated sample to washed YM-30 & centrifuge 14,000rpm 
~10min… Discard FT… 
 
□8.  Add 250µL UA… & centrifuge 14,000rpm ~10min… Repeat 2X’s… …
 
□9.  Add 100µL UB… & centrifuge 14,000rpm ~10min… Repeat 2X’s… … 
 
□10.  Add 50µL UB &  _____µL 1µg/µL Lysyl Endopeptidase (MS grade)… the
gentl
parafilm… Incubate digest ambient o/n…  ~_______hours… 
 
□11.  Add 0.2µL 0.5M CaCl2 & _____µL 1µg/µL MS grade Trypsin… then ge
mix ~1m… Incubate Trypsin digestion
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Appendix 3.  2D-high/low pH LC/MS protocol for ATRAP 
 
1.  Prepare 1st Dimension rpC18 column:  Cut _________mm X 250µm fused 
Wash with methanol again. Pack 5µ Jupiter C18 resin >150mm: ~_____mm. 
2.  P wash 
autosampler at 100µL/m 100% CapB (65% ACN). Backpressure:______bar. 
3.  Attach 75µm fused silica connect with 2µm SS nanofilter (head of 1st Dim. 
de) 
4.  Equilibra i n 5µ % Cap A (micro 
mode) for >1h. Shut off flow & allow pressure to drop slowly to avoid 
_________mm. 
method “LOAD.m” to start flow 10µL/min 100% CapA (micro/split flow 
, 0.2% 
ct 3-way T-connect.  
wing 5µL/min & 75µm connect (with 
1µm nanofilter) to 3-way T-connect. Attach 75µm connect to 10-port 
cessory Cap (dilution) pump backpressure: 
_______bar & 1st Dimension 5µ Jupiter C18 backpressure: __________bar. 
□8.  Set 10-port switching valve to position 1 “load trap” to pressure test. Record 
Accessory Cap (dilution) pump backpressure: __________bar & 1st 
Dimension 5µ Jupiter C18 backpressure: __________bar. 
 
□9.  Load method “LOAD.m” to equilibrate system for sample load (10-port 
switching valve to position 2 “inject trap”). Allow ~15min to equilibrate 
pressures & Record Accessory Cap (dilution) pump backpressure: 
________bar & 1st Dimension 5µ Jupiter C18 backpressure: ________bar. 
 
□10. Write hplc methods sequence _____________ to load & fractionate 
peptides. Print to file & double check sequence… 
 
□11. Thaw peptide sample & acidify… Centrifuge 14,000rpm, ~4C, 30min. 
Inspect for pellet & carefully transfer______µL supernatant to a low-
retention hplc sample insert. 
 
□12. Start sequence to run 2D-LC method… 
□
silica capillary tubing. Wash with methanol & assemble 1µm SS nanofilter. 
 
□ urge Capillary hplc pumps 10min each with high pH buffers & 
 
□
C18 column) to packed 5µ Jupiter C18 & wash at 20µL/min (micro mo
100% Cap B for >1h.  Backpressure: __________bar. 
 
□ te 1st Dimens o Jupiter C18 at 20µL/min 100
disturbing the column packing. Trim the head & measure: ~
 
□5.  Assemble 1st Dimension 5µ Jupiter C18 to autosampler 6-port & load 
mode).  Backpressure: __________bar. 
 
□6.  Start Accessory Capillary pump (dilution) flow at 50µL/min (3.5% ACN
FA) & conne
 
□7.  Attach 1st Dimension 5µ Jupiter C18 flo
switching valve. Record Ac
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